Bioorganic & Medicinal Chemistry Letters

A Tetrahedron Publication for Rapid Dissemination of Preliminary Communications on all Aspects of Bioorganic Chemistry, Medicinal Chemistry and Related Disciplines

Editor-in-Chief: **DALE L. BOGER**, *The Scripps Research Institute, La Jolla, CA 92037, USA*
Chairman of the Executive Board of Editors for Tetrahedron Publications: Sir Derek Barton, *Texas A&M University, USA*

SUBJECT INDEX AND AUTHOR INDEX
Volume 1 (1991)

Pergamon Press Oxford New York Seoul Tokyo

Bioorganic & Medicinal Chemistry Letters

A Tetrahedron Publication for Rapid Dissemination of Preliminary Communications on all Aspects of Bioorganic Chemistry, Medicinal Chemistry and Related Disciplines

Editor-in-Chief: **PROFESSOR D. L. BOGER,** Department of Chemistry, The Scripps Research Institute, 10666 North Torrey Pines Road, La Jolla, California 92037, USA
Fax: (619) 554 6401

EXECUTIVE BOARD OF EDITORS FOR TETRAHEDRON PUBLICATIONS
Chairman: **Professor Sir Derek Barton, FRS,** Department of Chemistry, Texas A and M University, College Station, Texas 77843–3255, USA

Professor J. E. Baldwin, FRS, Dyson Perrins Laboratory, Oxford, UK
Dr S. G. Davies, Dyson Perrins Laboratory, Oxford, UK
Professor L. Ghosez, Laboratoire de Chimie Organique de Synthèse, Université Catholique de Louvain, B-1348 Louvain-la-Neuve, Belgium
Professor S. Ito, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770, Japan
Professor A. R. Katritzky, FRS, Department of Chemistry, University of Florida, Gainesville, FL 32611, USA
Professor N. K. Kochetkov, N.D. Zelinsky Institute of Organic Chemistry, Academy of Sciences USSR, Leninsky Prospekt 47, Moscow B-334, USSR
Professor A. McKillop, University of East Anglia, School of Chemical Sciences, University Plain, Norwich NR4 7TJ, UK
Professor A. Nickon, Department of Chemistry, The Johns Hopkins University, Baltimore, MD 21218, USA
Professor W. D. Ollis, FRS, Department of Chemistry, University of Sheffield, Sheffield, S3 7HF, UK
Professor G. Ourisson, Centre National de la Recherche Scientifique, Centre de Neurochimie, 5 rue Blaise Pascal, 67084 Strasbourg Cedex, France
Professor T. Shioiri, Faculty of Pharmaceutical Sciences, Nagoya City University, Tanabe-dori, Mizuho-ku, Nagoya 467, Japan
Professor W. Steglich, Institut für Organische Chemie und Biochemie der Universität Bonn, D-5300 Bonn 1, Gerhard-Dogmagk-Strasse 1, Germany
Professor H. H. Wasserman, Department of Chemistry, Yale University, PO Box 6666, New Haven, CT 06511, USA
Professor W. T. Wipke, Thimann Laboratories, University of California, Santa Cruz, CA 95064, USA

BOARD OF CONSULTING EDITORS

P. Anderson, West Point, PA
S. Bell, Raritan, NJ
R. C. Breslow, New York, NY
P. N. Confalone, Wilmington, DE
S. Danishefsky, New Haven, CT
A. Eschenmoser, Zürich
A. K. Ganguly, Bloomfield, NJ
D. Gani, St. Andrews
G. L. Grunewald, Lawrence, KS
H.-J. Hess, Groton, CT
D. C. Horwell, Cambridge
W. L. Jorgensen, New Haven, CT
D. Keith, Nutley, NJ
R. Lerner, La Jolla, CA
D. Mansuy, Paris
B. W. Metcalf, King of Prussia, PA
W. H. Moos, Emeryville, CA
K. Mori, Tokyo
M. Ohno, Tokyo
H. Pearce, Indianapolis, IN
P. Potier, Gif-sur-Yvette
A. V. Rama Rao, Hyderabad
J. Rebek, Jr, Cambridge, MA
S. L. Schreiber, Cambridge, MA
T. J. Simpson, Bristol

Publishing, Subscription and Advertising Offices: Pergamon Press plc, Headington Hill Hall, Oxford OX3 0BW, UK and Pergamon Press Inc., 395 Saw Mill River Road, Elmsford, New York, 10523, USA.

Twelve issues per year

Annual Subscription Rates
Annual Institutional Subscription Rate (1992): £325 (US $520). Two-year Institutional Rate (1992/93): £617.50 (US $988). Sterling prices are definitive. US dollar prices are quoted for convenience only, and are subject to exchange rate fluctuation. Prices include postage and insurance and are subject to change without notice.
Subscription rates for Japan are available on request.

Specially Reduced Rates to Individuals
In the interests of maximising the dissemination of the research results published in this important international journal we have established a two-tier price structure. Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use, rates available from your nearest Pergamon Office.

Microform Subscriptions and Back Issues
Back issues of all previously published volumes are available direct from Pergamon Press offices.

The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences—Permanence of Paper for Printed Library Materials. ANSI Z39.48 1984.

The Item-Fee Code for this publication is: 0960–894X/91 $3.00 + .00

Copyright © 1992 Pergamon Press plc
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

Photocopying Information for Users in the USA
The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying, beyond that permitted by Section 107 or 108 of the United States Copyright Law, is paid. The appropriate remittance of $3.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 27 Congress Street, Salem, MA 01970.

Permission for Other Use
The copyright owner's permission does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying.

Subject Index 1991

Azaacenaphthalenes
substit 5–amino–8–phenyl–3H,6H–1,4,5a,8a–tetraazaace–naphthalene–3–ones, cognition improvement, 435

Acetylcholinesterase
inhibitor, 9–amino–1,2,3,4–tetrahydro–acridine 2–positions varying log *P*, *log* D and pKa values, 411
inhibitor, optically active 8–carbaphysostigmine analog, 47
inhibitors, synthesis and biological activity galanthamine derivs, 579

N–Acetylcysteamine
thioesters, isotopically labelled, 223

Acids
tryptophanylphenethylamides, stability, 169

Activity
activated cephalosporin–oncolytic prodrug, cancer, delivery system, 21
3–nitrosteroid inhibition of 5α–reductase, 27
positive inotropic, 2–aryl–1,2–dihydro–67–dimethoxyquin–azoline–3–oxides, 133
structure relationships, monocyclic endothelin analogs, 33

Acyliminium ion
route to *cis* and *trans* 'anti' phenylalanylglycine mimetics, 309

Adenosine
A1, receptors, high selectivity of iso– guanosine analogs, 481
analogs, prep 4– amino–1–(β–D–ribofuranosyl) pyrrolo[2,3–d] pyridazine, 111
introduction of 6–N–(2–cholesr–eroloxycarboaminoethyl)– or 6–N–[2–(fluorenylmethoxycarbo amino)ethyl]– moieties, 487
S–adenosylmethionine decarboxylated restricted rotation analogs, inhibited polyamine biosynthesis, 267

Agonists
acetylcholine–receptor muscarinic–, pilocarpine 2–oxazolidinone analog, 147
adenosine A1 receptor–, highly selective isoguanosine analogs, 481
dopamine–,4,5,6,7–tetra–hydrobenzothiazole low stereoselectivity interaction dopamine receptors, 189
dopamine–, PD128483 enantiomers, synthesis and activity, 539
specific GABAA receptor–,(±)–2–amino–2–thiazoline–4–ethanoic acid, 247

Alcalase
catalyzed peptide bond formation in organic solvent, 445

Alkali
tryptophanylphenethylamides, stability, 169

Alkylation
DNA–, semicarbazide deriv CC–1065 analog, 55

3–Acylamino–2–carboxyindole
NMDA receptor glycine–site antagonists, 455

Amidine
linked and phenyl– containing analogue of distamycin A, synthesis and DNA binding properties, 595

Amphiphile
telomeric–, with trishydroxy–methyl groups, fluorinated, biocompatible, non–ionic, 103

Aminocyclopropane
carboxylic acid derivs and analogs, substrate activated time dependent inhibition of carboxypeptidase A, 557

Aminopepidase
activity, basis of LTA4 hydroxylase inhibition, 551

Aminophosphonic acid
3–amino–2–(4–chlorophenyl)1,1–d ofluoropropyl phosphonic acid, synthesis and biological evaluation, 501

3–Aminomethyltetralones
5HT2–antagonist activity, 717

Amino–prostanoids,
pyridine–containing–, synthesis and evaluation thromboxane receptor antagonist/thromboxane synthase inhibitor, 695
synthesis and evaluation as thromboxane A2 receptor anragonists, 689

Amylin amide
rat–, mercury complex in commercial sources, 415

5α–Androstane–3,17–dione
biotransformation by microalgal cultures, 673

Antagonists
5–HT2–, activity 3–amino–methyl–, tetralones, 717
active PAF receptor–, activity MK 287 (L–680,573), 327
glutamate–, conform ationally–restricted 3(*S*)–phosphonoacetyl–2(*R*)–piperidine–ccarboxylic acid, synthesis, 441
glycine–site–, NMDA receptor, design, synthesis and molecular modeling of 3–acylamino–2–carboxyindole, 455
non–peptide–, angiotensin II, synthesis of bromobenzofurans, 711
non–peptide P–, prepn, radiolabelling CP–96,345, 129
receptor–, thromboxane A2, synthesis and evaluation of aminoprostanoids,689

terfenadine–, VUF4567 and VUF4568 optical isomers, synthesis, 387
thromboxane–, long–acting, inter–phenylene 7–oxabicyclo–[2.2.1]heptane SQ 33,961, 461
thromboxane receptor/ thromboxane synthase inhibitor, pyridine containing amino–prostanoids, 695
thromboxane receptor–, synthase inhibitor, pyridine containing sulphonamido acids,699
thromboxane receptor–, structural homologs interaction with TXA2 receptors, 173
thromboxane–, SQ 33,961, conformionally restricted analogs, receptor binding conformation of carboxyl side–chain, 465

Angiotensin–II
bromobenzofurans non–peptide antagonists, 711
converting enzyme inhibition, synthesis of (*R,S*)–captopril–F3, 581

Anhydroalditols
interaction sweet– almond β–glucosidase and and *E.coli* β–galactosidase, design glycosidase inhibitors, 667

Antibody
β–lactamase conjugate activated cephalosporin–oncolytoc prodrug, cancer, 21

Antibiotics
5,11–dithiopyrrolo–[1,4]–benzodiazepine, enzymatic biooxi– dative conversion 5–thio to 5–oxo, 159
and antiviral combined prodrugs O–alkyl–5,5'–dinucleoside phosphates, 527
blasicidin S, biosynthesis, cell free demonstration N–methylation as last step, 497
ionomycin C_{11}–C16 subunit, synthesis via Baeyer–Villiger oxidation, 535
monocyclic γ–lactams activated by hydroxycyclobutane–dione, prep, 737

Anticancer agents
araC, masked phosphate derivs via trans–esterification, 607

Antidepressant drugs
R–(–)–thiazesim hydrochloride, enantioselective chemo–enzymatic synthesis, 383

Antifungal agents
blasicidin S, biosynsynthesis thesis, cell free demonstration N–methylation as last step, 497
Sch 42457 (SM 9164), 349

Antihistamines
H1 terfenadine, optical isomers, synthesis and activity, 387

AntiHIV agents
(+/–)–1'–aza–carbocyclic pyrimidine–2',3'–dideoxy–nucleoside analogs, synthesis, 757
anti–AIDS agents, 1'–N–replaced carbocyclic thymidine analogs, 287
FDT studies, introduction chemotheropeutic nucleotides into cells,729
geometric isomers DDC, DDA, D4C and D4T, 65
potential inhibitor, pyrimidine TIBO analog, 531
protease inhibitors, C2–and pseudo–symmetric from D–arabitol, 219
protease inhibitors, phosphonamidates and phosphonamidate esters, 653
reverse transcriptase inhibition, AZT 5'–triphosphate difluoromethylene phosphonate analog, 357

Antihuman rhinovirus 14
activity, synthesis new disoxaril analogues, 575
efficient agent, modification of oligonucleotides, solid phase synthesis, 487

Antimalarial agents
activity, 12–(3'–hydroxy–n–propyldeoxoartmisinin, synthesis, 741

Antihypertension
benzopyran–related potassium channel activators, role for lipophilicity, 591
SGB–1534 and ketanserin, synthesis conformationally restricted analogues via quinazolinones, 571
WAY–120,491, structure K–channel activator, 39

Antithrombin III
6–O–phosphorylated analog, binding sequence of heparin, synthesis, 143
binding site of porcine mucosa heparin, 99

Antitubulin agents
tricyclic phenylpyrrole lactams, synthesis, 725

Antitumor agents
bouvardin,deoxy– bouvardin and RA–I–RA–VII, partial structures, pharmacophore reassignment, 313
CC–1065 alkylation subunit analog, potent deriv, 55
CC–1065(+), evaluation (+)–CBI–indole functional analog, 115
new compds, keto C–glycoside, 395
potency, optically active 4,4–difluorothreonine, 271

Antiviral agents
9–[2,2–bis(hydroxymethyl) cycloprop–1–yl]guanine potential, 347
and antibiotic combined prodrugs O–alkyl 5,5'–5,5'–dinucleoside phosphates, 527

Arenes
arene fused prostacyclin analog, synthesis, 77
arene fused prostacyclin analogs related U68,215, triply–convergent syntheses, 79
aryl boronic acid bound to chymo trypsin and subtilisin, ^{11}B NMR, 9
aryl ring systems and tubulin binding, 243

Artemisinin
12–(3'–hydroxy–n–propyl)–deoxo artemisinin, antimalarial activity, synthesis, 741

Asymmetric synthesis
azepane–2–carboxylic esters, 125

Assays
continuous spectrophoto–metric–, phosphate substrate for phosphatidylinositol–specific phospholipase C,hexadecyl–thiophosphoryl–1–*myo*–inositol, 615
phosphatidylinositol–specific phospholipase C, fluores–cent substrate 4–(1–pyreno) butylphosphoryl–1–*myo*–inositol 619

Autophosphorylation site
insulin receptor corresponding tri–phosphorylated peptide, conformational comparison non–phosphorylated analog, 299

Avermectin
analogs, spacer between aglycone and disaccharide, 369

Azepane–2–carboxylic acid
esters, asymmetric synthesis, 125

Azetidinones
3–alkyl–4–azetidinones, human leukocyte elastase–mediated lung damage prevention,545–

AZT
5'–triphosphate, difluoro–methylene phosphonate analog, inhibition HIV–1 reverse transcriptase, 357

Baker's yeast
catalysed oxidative coupling, disulfides to thiols, 507

D2O reduction, use isotopical labelling N–acetylcysteamine, 223

Benzazepine
LY134046, regioselective synthesis, phenylethanol–amine N–methyltransferase inhibitor, 59

Benzodiazepine
5,11–dithiopyrrolo[1,4]–deriv, biooxidative conversion 5–thio to 5–oxo, 159

Benzoindane
fused prostacyclin analog, homochiral triply–convergent synthesis, 73

Benzoindenones
bioactive–, from *Eichhornia crassipes* Solms, 599

Benzothiazepines
4–(5H)–one(2–phenyl–benzothiaze pin, optically active, synthesis, 383

Bioconversion
5α–androstane–3,17—dione by microalgal cultures, 673

Biological activity
avermectin analogs, spacer between aglycone and disaccharide, 369
benzoindenone from *Eichhornia crassipes* Solms, 599
evaluation of 3– amino–2–(4–chlorophenyl)–1,1–difluoroprop yl phosphonic acid, 501
evaluation, arene–fused prostacyclin analog, 77
fluorinated intermediates for methionine salvage pathway, 623
important *myo*–inositol phosphorothioates, 239
inactivity, 6–O–phosphoryl–ated analog antithrombin III binding sequence heparin, 143
MK 287 (L–680,573), active PAF receptor antagonist, 327

Biomimetic oxidation
21–hydroxy, 21– formyl and 21–carboxylic pregn–4–en–3,20–dione with chemical cytochrome P450 model systems, 601

Biosynthesis
blasicidin S, cell free demonstration N–methylation as last step, 497
cephalosporin, role of sulfur, 421
leukotriene inhibitors, ((4–(4–chlorophenyl)–1–(4–(2–quinol—inylmethoxy)phenyl)butyl)thio) acetic acid, L–674,636, 645
preuroporphyrinogen by PBG deaminase, enzyme bound intermediates, 503

Blasticidin S
biosynthesis, cell free demonstration N–methylation as last step, 497

Blood
3–alkyl–4–azetidinone human leukocyte elastase–mediated lung damage prevention, 545
PAF active receptor antagonist, activity MK 287 (L–680,573), 327
platelet aggregation inhibitor, two arene–fused prostacyclin analogs related U68,215, 79

Boronic acid
aryl boronic acid, bound to chymotrypsin and subtilisin, ^{11}B NMR, 9

Bouvardin
bouvardin, deoxybouvardin and RA–I–RA–VII, partial structures, pharmacophore reassignment, 313

Brain
uptake, physical parameters, optimizing log *P*, log *D* and pKa of THA, 411

Bromobenzofurans
new class–, non– peptide antagonists angiotensin II, 711

Calcium
channel blocker dihydro–pyrimidine mimics dihydro–pyridine, 291

Cancer
antibody β–lactamase conjugate activated cephalosporin–oncolytic prodrug, 21
nucleoside analogs, chemoreversible prodruds of ARA–C, synthesis, 745
rat hepatocarcinoma cells, cytotoxic evaluation keto–C–glycoside fatty acid conjugates, 721

Candida albicans
growth inhibition by benzo–indenone from *Eichhornia crassipes* Solms, 599

Captopril–F3
(*R,S*)–, synthesis and ininhibition of angiotensin converging enzyme, 581

Carbacephalosporin
spermine–based tricatecholate conjugate, biological activity, 513

Carbocyclin
analogs(2), cyclopent[a]indene, homochiral, triply– tconvergent synthesis,83

Carbonic anhydrase
water–soluble inhibitors, 2–substit 1,3,4–thiadiazole–5–sulfonamide s, 407

Carboxyallenyl phosphate
EPSP synthase inhibitor, 683

Carboxylic acids
amides of 3–amino– substit indole–2 carboxylic acids, glycine–site antagonists, 455
carboxyl oxygen, intramolecular nucleophilic displacement, 13

Carboxypeptidase A
function S1' subsite pocket, 323
structure S1' subsite, 317
substrate activated time dependent inhibition by amino–cyclopropane carboxylic acid derivs and analogs, 557

Cardiotonic agents
activity,2–aryl–1,2–dihydro–6,7–dimethoxyquinazoline–3–oxides, 133

Cardiovascular drugs
monodeoxy–1,3,2,6–dianhydrohex itol nitrates, synthesis, 629
monodeoxy–1,3,2,6–dianhydrohex itol nitrates, synthesis, 629

Catechol
bioisosteres, dopamine receptor ligands, 403

(+)–CBI–indole
functional analog (+)–CC–1065, evaluation, 115

(+)–CC–1065
evaluation (+)–CBI–indole functional analog, 115

Cells
introduction chemotherapeutic nucleotides, FDT studies, 729
viability, purple water soluble formazan indicators via MTS inner salts and related analogs of MTT, 611

Cephalosporin
biosynthesis, role of sulfur, 421
oncolytic prodrug, cancer, targeted delivery system, 21

Chemoenzymatic synthesis
branching decasaccharide fragment, capsular polysaccharide, type III group B *Streptococcus* 391
enantioselective synthesis, R–(–)–thiazesim hydrochloride, 383
L–galactopyranosyl serine, 197

Chemotherapy
introduction nucleotides into cells, FDT studies, 729

Chloramphenicol
FT–IR evidence intramolecular H–bond, 253

Chloinergic agents
2–oxazolidinone analogs, acetyl–

choline–receptor muscarinic agonist pilocarpine, 147

Chlorophyceae
cultures, 5α–androstane–3,17–dione biococnversion, 673

Chymotrypsin
bound aryl boronic acid, ^{11}B NMR, 9

Circulatory system
cooperativity enhanced transport, 87

Coenzymes
Co A reductase, HMGR, phosphinic acid inhibitors, 151
CoA reductase, HMG, substrate–based inhibitors, 61
CoA reductase–II, HMG, substrate– based inhibitors, 161
route to N^5–formyltetrahydro–pteroylpoly–L–glutamates, 155

Cognition improvement
via substit 5–amino–8–phenyl–3H,6H–1,4,5a,8a–tetraazaacenaphthalen–3–ones, 435

Colchinine
analogs, tubulin binding, structural requirements, role of C–10 substituent, 471

Combretastatin
bisaryl analogs, tubulin polymerization inhibited, 243

Complexes
enzyme/boronate, ^{11}B NMR evidence, 9
$Pd_2(CH_3NC)_6^{2+}$ and $Pt_2(CH_3NC)_6^{2+}$, DNA nicking properties, 451

Comformation
oligothymidylates with sulfur modified thymidine, effect of thiation of pyrimidine ring, 523
preference/potency, GnRH analogs, NMR, 263
restricted thromboxane antagonist analogs, SQ 33,961, receptor binding conformation of carboxyl side– chain, 465

Cooperation
cooperativity enhanced transport through circulating system, 87

Coupling reactions
oxidative–, thiols to disulfides, baker's yeast catalysed, 507

CP–96,345
non–peptide P antagonist, prepn, radiolabelling, 129

Cyclases
oxidosqualene–, pig liver and yeast, behaviour epoxy–squalene analogs with 18 19Z or *E* C, C double bond, 365

Cyclopent[a]indene
carbacyclin analogs(2), homochiral, triply– convergent synthesis, 83

Cytochrome
P–450 oxidation 1–methyl–cyclohexene, hydroxylation, epoxidation and stereochemistry of epoxidation, 121
P450 chemical model systems, biomimetic oxidation 21–hydroxy, 21–formyl and 21–carboxylic prepn–4–en–3,20–dione, 601

Cytotoxicity
evaluation,keto–C– glycoside fatty acid conjugates, 721
evaluation, structure S1' subsite carboxypeptidase A, 317
semicarbazide deriv CC–1065 analog, 55
tricyclic phenylpyrrole lactams, antitubulin agents, synthesis, 725

Degradation
microbial, [^{32}P]–ethylphos–phonate, organophosphonate C–P bond cleavage, 51

Dehalogenation
by bacteria, stereospecific, generation (*R*)–and (*S*)–3–chloro–1,2–propanediol, prep (*R*)– and (*S*)–glycidol, 343

Delivery systems
activated cephalosporin–oncolytic prodrug, cancer, 21

Deoxyribonuclease
DNA, DDC, DDA, D4C and D4T geometric isomers, anti–HIV agents, 65
DNA binding properties and synthesis amidine–linked and phenyl–containing analog of distamycin A, 595
supercoiled DNA, nicking by metal radicals generated from species with metal–metal bonds, 451

Disoxaril
analogs with anti–human rhinovirus 14 activity, synthesis, 575

Displacement reaction
intramolecular nucleocleophilic–, carboxyl oxygen, 13

Disulfides
to thiols, baker's yeast catalysed oxidative coupling, 507

Dopamine
agonist 4,5,6,7–tetrahydro–benzothiazole, low stereo–selectivity interaction dopamine receptors, 189
agonist PD128483, enantiomers, synthesis and activity, 539
receptor ligands, catechol bioisosteres, 403

Distamycin A
amidine–linked and phenyl–containing analogue, synthesis and DNA binding properties, 595

Eichhornia crassipes
isolation of bioactive benzoindenone, 599

Enantiomers
8–carbophysostigmine analog, acetylcholine esterase inhibitor, 47
ethyl 4,4,4–trifluoro–3–hydroxy butanoate by microbial reduction, 675
geometric isomers DDC, DDA, D4C and D4T, anti–HIV agents, 65
L–2,2–difluoro–2–deoxy–*myo*–inositol 1,4,5–triphosphate, synthesis, 705

Enantioselection
chemoenzymatic synthesis, *R*–(–)–thiazesim hydrochloride, 383
enzymatic reactions reversible by media, 339
increased by temp and DMSO, hydrolysis methyl alkyl di–methylmalonates, esterase catalysed, 373
synthesis and pharmacological profile 12–deoxy–12–(*S*)–methyl leukotriene B_4, 179

Enantiospecificity
synthesis 14*S*,15*S* leukotriene A4 methyl ester, 201

Endothelin
monocyclic analogs, activity–structure relationships, 33

Enzymatic reactions
and nonenzymic lipid peroxidation, inhibition substit phenoxazines, 107
enantioselively reversed by media, 339
regioselective oxidative conversion, 5–thio to 5–oxo in 5,11–dithiopyrrolo–[1,4]benzodiazepine antibiotics, 159
syntheses, D– and L–*myo*–inositol–1–phosphorothioate, substrates for inositol monophosphatase, 17

Enzymes
bound intermediates, biosynthesis preuroporphyrinogen by PBG deaminase, 503
boronate complex, ^{11}B NMR evidence, 9
D–*myo*–inositol1,4,5–trisphos–phate, synthesis 2,2–difluoro–2–deoxy*myo*inositol 1,4,5–trisphosphate, 705

Epidermis
epidermal growth factor receptor and tyrosine–specific protein kinases, styryl–based inhibitors, structural influences, 165

Epoxidation
steric course, hydroxylation, cytochrome P–450 oxidation 1–methylcyclohexene, 121

EPSP Synthase
inhibitors, PEP structural analogs, 683

Escherricha coli
β–galactosidase inhibition by anhydroalditols, 667
degradation, [^{32}P]–ethyl phosphonic acid, organophosphonate C–P bond cleavage, 51
siderophore growth promoting activity compds, 513

Esterase
catalyzed hydrolysis methyl alkyl dimethylmalonates, enantioselectivity increased by temp and DMSO, 373

Esterification
2–(4–chlorophenoxy)propionic acid enantioselectively reversed by media, 339
trans–esterification yielding masked phosphate derivs of anti–cancer agent araC, 607

Ethyl 4,4,4–trifluoro–3–hydroxybutanoate
prep enantiomers by microbial reduction, 675 Ethylphosphonic acid

Ethyl phosphonic acid
microbial degradation, organophosphonate C–P bond cleavage, 51

Fatty acids
keto–C–glycoside conjugates, design, synthesis and cytotoxic evaluation, 721

FKBP
identical to PKCl–2? non inhibition protein kinase C, 205

Fluorescent compounds
substrate for assay, phosphatidylinositol–specific phospholipase C, 4–(1–pyreno) butylphosphoryl–1–*myo*–inositol 619

Fluorine compounds
α–fluoro analog of GABA$_B$ antagonist phaclofen, synthesis, 501
7–fluorotryptophanes, resolution and synthesis, 477
fluorinated intermediates for methionine salvage pathway, synthesis and biological activity, 623
fluorinated non–ionic surfactants, telomeric amphiphiles with trishydroxymethyl groups, 103
fluorothreonine(4,4–di–) optically active, antitumor potency, 271

Formazan
purple water–soluble cell viability indicators via MTS inner salt and related analogs of MTT, 611

Fucosyltransferase
recombinant synthesis, sialyl Le^x and derivs, 425

GABA
GABAA specific agonist receptor, (±)–2–amino–2–thiazoline–4–et hanoic acid, 247
GABAB antagonist phaclofen, synthesis α–fluoro analog, 501

β–Galactosidase
E.coli–, inhibition by anhydroalditols, 667
galactopyranosyl–L–serine, ssstereospecific chemoenzymatic synthesis, 197

Galanthamine
derivs, synthesis and acetylcholinesterase inhibition, 579

D–Glucofuranoyl sugars
glycosylation with 4,6–bis–(methylthio)pyrazolo[3,4–*d*]–pyrimidine, 249

Glucosamine
replaced by glucose fragment in heparin–like pentasaccharide, 95

Glucose
D–, 6–phosphorothioate, not a substrate for inositol synthase, 17
replacing glucosamine fragment in heparin–like pentasaccharide, 95

β–Glucosidase
sweet–almond–, inhibition by anhydroalditols, 667

Glucosidol
(*R*)–and (*S*)–, via generation (*R*)–and (*S*)–3–chloro–1,2–propanediol, 343

Glutamate
antagonist, conformationally–restricted 3(*s*)–phosphono–acetyl–2(*R*)–piperidinecarboxylic acid, synthesis, 441

Glutathione
peroxidase, redox chemistry active site model peptides, 277

Glycine
site antagonist, NMDA receptor, design, synthesis and molecular modeling of 3–acylamino–2–carboxyindole, 455
strychnine–insensitive glycine site, tricyclic quinoxaline ligands, 751

Glycosides
keto C–, antitumor compds, 395
keto–C–, fatty acid conjugates, design, synthesis and cytotoxic evaluation, 721
methyl–, decasaccharide, mapping antibody combining site at molecular level, 391

Glycosylation
4,6–bis(methylthio)pyrazolo [3,4–*d*]pyrimidine with D–glucofuranosyl sugars, 249

GnRH
analogs conformation preference/potency, NMR, 263

Growth
inhibitors for *Tryptanosoma cruzi*, activity of juvenile hormone analogs, 679

Guanine
9–[2,2–bis(hydroxymethyl)cyclo–prop–1–yl]–guanine, potential antiviral agent, 347

Heparin
antithrombin III binding sequence, replacement essential sulphate group by phosphate group nullifies biological activity, 143
heparin–like pentasaccharide fragment with glucose instead glucosamine, 95
porcine mucosa, prep antithrombin III binding site, 99

Hexadecylthiophosphoryl–1–*myo*–inositol
phosphate substrate for continuous spectrophotometric assay phosphatidyl–inositol–specific phospholipase C, 615

HMG–CoA
reductase monocyclic inhibitors, C–2 desmethyl seco– mevinic acids, 509

Hormones
juvenile–, analogs, *Tryptanosoma cruzi* growth inhibitors, 679

Hydrogen bond
intramolecular–, chloramphenicol, FT–IR evidence, 253

Hydrolysis
esterase catalyzed, methyl alkyl dimethylmalonates, enantioselectivity increased by temp and DMSO, 373

Hydrophobic serine
protease model, 353

Hydroxycyclobutenedidione
activated monocyclic γ–lactam antibiotics, 737

Hydroxamic acid
cyclic aryl–, inhibition 5–lipoxygenase, 295

Hydroxylation
epoxidation, steric course, cytochrome P–450 oxidation 1–methylcyclohexene, 121

Imidazo[1,2–*a*]piper—azines
mechanistic inhibitors serine proteinases, 69

Inflamatory activity
Thorecta horridus linear sesterterpenes, 639

Inhibition
2,3–α–methylene– penicillanic acid sulfone synthesis by β–lactamase, 43
3–hydroxy–3–methylglutaryl–coen zyme A reductase by phosphinic acid, 151
5α–reductase by 3–nitrosteroids, mechanism and activity, 27
5–lipoxygenase by cyclic aryl hydroxamic acid, 295
acetylcholinesterase–, synthesis and biological activity galanthamine derivs, 579
angiotensin converting enzyme–, synthesis of (*R,S*)–captopril–F3, 581
C2–symmetric and pseudo–symmetric HIV–1 protease inhibitors from D–arabitol and D–mannitol, 219
carbonic anhydrase–, by water soluble 2–substit 1,3,4–thiadiazole–5–sulfonamides, 407
enzymic and nonenzymic lipid peroxidation–, by substit phenoxazines, 107
glycosidase inhibitors, design, interaction anhydroalditols with sweet–almond β–glucosidase and *E.coli* β–galactosidase, 667
growth–, *Tryptanosoma cruzi*, activity of juvenile hormone analogs, 679
HIV–1 reverse transcriptase–, by AZT 5'–triphosphate difluoromethylene phosphonate analog, 357
imidazo[1,2–*a*]piperazines, mechanistic inhibitors serine proteinases, 69
in vitro and *in vivo*–, prolyl endopeptidase, 585
L–2,2–difluoro–2–deoxy–*myo*–ino sitol 1,4,5–trisphosphate–, enzymes of D– *myo*–inositol 1,4,5–trisphosphate metabolism, 705
L–674,636–, leukotriene biosyn– thesis, 645
LTA4 hydroxylase–, based on its aminopeptidase activity, 551
monocyclic HMG–CoA reductase–, C–2 desmethyl seco– mevinic acid, 509
optically active 8–carba–physostigmine analog, acetylcholinesterase inhibitor, 47
PEP structural analogs–, EPSP synthase, 683
phenylethanolamine N–methyltransferase–, by LY134046, 59
phosphonamidates and phosphonamidate esters as HIV–1 protease inhibitors, 653
polyamine biosynthesis–, by restricted rotation analogs decarboxylated 5–adenosyl–methionine, 267
potential HIV–1–, pyrimidine TIBO analog, 531
protein–tyrosine kinase–, by phenylhydrazones, 215
protein–tyrosine kinase–, by pyridine–stilbenes and –amides, 211
squalene epoxidase–, by 26–hydroxysqualene and derivs, 227
structural influences styryl–based inhibitors on epidermal growth factor receptor and tyrosine–specific protein kinases, 165
substrate–based inhibitors, HMG CoA reductase, synthesis, 61
tetrahydroacridine deriv–, optimizing log *P*, log *D* and pKa, brain uptake, 411
thromboxane receptor antagonist/thromboxane synthase inhibitor, pyridine containing amino–prostanoids, 695
time dependent–, substrate activated, carboxypeptidase A by aminocyclo–propane carboxylic acid derivs and analogs, 557

Inositol
IP3 analog with *p*–azidobenzoyl and biotinyl moieties, photoaffinity probe, 399
L–2,2–difluoro–2–deoxy–*myo*–inosito 1,4,5–trisphosphate inhibitor enzymes of D–*myo*–inositol 1,4,5–trisphosphate metabolism, 705
monophosphatase catalysed phosphate–oxygen exchange, 193
monophosphatase, D– and L–*myo*–inositol 1–phosphoro–thioate substrates, 17
myo–, phosphorothioates, biologically important, 239
synthase, D–glucose 6–phosphorothioate not a substrate, 17

Inotropic activity
2–aryl–1,2–dihydro–6,7–dimethox y–quinazoline–3–oxides, 133

Insulin
receptor autophosphoryl–ation site corresponding tri–phosphorylated peptide, conformational comparison non–phosphorylated anlog, 299

Interphenylene 7–oxabicyclo [2.2.1]–heptanes
SQ33,961, thromboxane long–acting antagonist, 461

Intramolecular reactions
nucleophilic displacement, carboxyl oxygen, 13

Ionomycin
C11–C16subunit, synthesis via Baeyer–Villiger oxidation, 535

Isomers
geometric–, DDC, DDA, D4C and D4T, anti–HIV agents, 65

Isoguanosine
analogs, highly selective adenosine A1 receptors, 481

Keptanserin
and SGB–1534, antihypertensive agents, synthesis conform–ationally restricted analogues via quinazolinones, 571

Keto–C–glycoside
antitumor compds, 395
fatty acid conjugates, design, synthesis and cytotoxic evaluation, 721

Ketophosphonic acid
conformationally–restricted 3(*S*)–phosphonoacetyl–2(*R*)–piperidinecarboxylic acid, glutamate antagonist, synthesis, 441

Kinase
protein kinase C not inhibited by FKBP, identical? PKCl–2, 205
protein–tyrosine–, inhibitors of phenylhydrazone, 215
protein–tyrosine–, inhibitors of pyridine–containing stilbenes and amides, 211

Labelled compounds
isotopically, N–acetyl–cysteamine thioesters, 223

β–Lactamase
antibody conjugate activated cephalosporin–oncolytic prodrug, cancer, 21
antibody conjugate inhibition,2,3–α–methylene–penicillanic acid sulfone syn–thesis, 43

Lactams
monocyclic γ–lactams activated by hydroxycyclobutenedione antibacterial agents, 737
tricyclic phenylpyrrole, antitubulin agents, synthesis, 725

Lactonisation
Kemp triacid derivs, 13

LFCl2A
cells, cytotoxic activity keto C–glycosides, 395

Leukotriene
14*S*,15*S*–LTA4 methyl ester, enantiospecific synthesis, 201
biosynthesis inhibitors, ((4–(4–chlorophenyl)–1–(4–(2–q uinolinylmethoxy)phenyl–butyl)thio) acetic acid, L–674,636, 645
LTA4 hydroxylase inhibition based on its aminopeptidase activity, 551
LTB4,12–deoxy–12(*S*)methyl deriv, deriv,enantioselect–ive synthesis and pharmacologic profile 179

Lipids
peroxidation, enzymic and nonenzymic, inhibition substit phenoxazines, 107

Lipophilicity
role, hypertensive benzopyran–related potassium channel activators, 591

5–Lipoxygenase
inhibition, cyclic aryl hydroxamic acids, 295

Lungs
damage, human leukocyte elastase–mediated, prevention by 3–alkyl–4–azetidinone, 545

Manducta horridus
sex pheromonal components, stereospecific synthesis (*E,E,Z*)– and (*E,E,E*)–10,12–14–hexadecatrienal, 635

Mass spectrometry
electrospray–, enzyme bound intermediates in preuroporphyrinogen biosynthesis by PBG deaminase, 503

Mechanisms
3–nitrosteroids, 5α–reductase inhibition 27
substrate recognition carboxypeptidase A, 323

Mercury
complex in commercial sources, rat amylin amide, 415

Metabolism
enzymes of D–myo–inositol, 1,4,5–trisphosphate, synthesis L–2,2–difluoro–2–deoxy–*myo*–inositol 1,4,5–tris–phosphate, 705

Metabolites
P–, organophosphonate C–P bond cleavage, degradation [^{32}P]–ethylphosphonic acid, 51

Metals
radicals generated from species with metal–metal bonds, nicking of supercoiled DNA, 451

Methionine
salvage pathway, fluorinated intermediates, synthesis and biological activity, 623

Methylalkyl dimethylmalonates
esterase catalyzed hydrolysis, enantioselectivity increased by temp and DMSO, 373

Methylcyclohexene
cytochrome P–450 oxidation, steric course, epoxidation, hydroxylation, 121

α–Methylenepenams
as cephalosporins, 43

Methylene pencillanic acid sulfone
β–lactamase inhibition, 43

Mevinic acid
C–2 desmethyl seco–mevinic acids, monocyclic HMG–CoA reductase inhibitors, 509

Microorganisms
microalgal cultures, 5α–androstane–3,17–dione biococnversion, 673
reduction, ethyl 4,4,4–trifluoro–3–hydroxy butanoate, prep enantiomers, 675

Mimetics
cis and *trans* 'anti' phenylalanylglycine via acyliminium ion, 309

Models
molecular–, 3–acylamino–2–carboxyindole, NMDA receptor glycine–site antagonist, 455
chemical cytochrome P450 systems, biomimetic oxidation 21–hydroxy, 21–formyl and 21–carboxylic pregn–4–en–3,20–dione, 601

Monophosphatase
inositol–, catalysed inositol phos–phate–oxygen exchange, 193
inositol–, D– and L–*myo*–inositol 1–phosphorothioate substrates, 17

Muscarinic activity
acetylcholine receptor agonist, pilocarpine 2–oxazolidinone analog, 147

Named reactions
Baeyer–Villiger oxidation, synthesis ionomycin C11–C16 subunit, 535

Neisseria meningitidis
vaccine, sugar–peptide conjugate, approach synthesis, 303

Nitrates
monodeoxy–1,3,2,6–dianhydrohex itol–, synthesis, 629

Nitro compounds
3–nitrosteroids, 5α–reductase inhibition, mechanism and activity, 27

Nucleophilic reactions
intramolecular displacement, carboxyl oxygen, 13

Nucleosides
(+/–)–1'–aza–carbocyclic–pyrimid ine–2',3'–dideo x y nucleoside analogs, anti HIV agents, 757
1'–N–replaced dideoxy carbocyclic pyrimidine anti–AIDS agents, 287
9–[2,2–bis(hydroxymethyl)cyclo–p rop–1– yl]guanine potential antiviral agent, 347
nucleoside analogs, chemoreversible prodruds of ARA–C, synthesis, 745
O–alkyl–5,5'–dinucleoside phosphates combined antiviral and antibiotic prodrugs, 527

Nucleotides
chemotherapeutic–, introduction into cells, FDT studies, 729

Oligonucleotides
efficient–, deriva tization protocol, 487
oligothymidylates with sulfur modified thymidine, thermo–stability and conformation, effect of thiation of pyrimidine ring, 523

Organophosphates
C–P bond cleavage, microbial degradation [^{32}P]–ethylphosphonic acid, 51

Oxabycyclo[2.2.1]heptanes
interphenylene–, SQ 33,961, thromboxane long–acting antag–onist, 461

Oxazoles
oxabicycloheptane–, SQ 33,961, thromboxane long–acting antagonist, 461

Oxidation
biomimetic–, 21– hydroxy, 21–formyl and 21–carboxylic prepn–4–en–3,20– dione with chemical cytochrome P450 model systems, 601

Oxygen
carboxyl–, intramol–ecular nucleophilic displacement, 13

Pentasaccharides
DEFGH sequence in heparin antithrombin III binding site, 99
heparin–like fragment with glucose instead glucosamine, 95

PEP
(Z)–3–3fluoro–, EPSP synthase inhibitor, 683
PEP, structural analogs, inhibitors EPSP synthase, 683

Peptides
active site model redox chemistry, peroxidase glutathione, 277
bond formation in organic solvent, catalyzed by 'alcalase', 445
cis and *trans* 'anti' dipeptide, mimetics via acyliminium ion, 309
triphosphorylated–, corresponding autophosphorylation site insulin receptor, con–formational comparison non–phosphorylated analg, 299

Peroxidase
glutathione, redox chemistry active site model peptides, 277

Pharmacophore
partial structures bouvardin, deoxybouvardin, and RA–I–RA–VII, 313

Phenoxazine
inhibition enzymic and nonenzymic lipid peroxidation, 107

Phenylalanylglycine
cis and *trans* 'anti', mimetics via acyliminium ion, 309

Phenylethanolamine
N–methyltransferase inhibitor, regioselective synthesis, 59

Phenylhydrazones
inhibitors, protein–tyrosine kinase, 215

Pheromones
sex components of *Manducta sexta*, stereospecific synthesis (*E,E,Z*)– and(*E,E,E*)–10,12, 14–hexadecatrienal, 635

Phosphatase
myo–inositol 1,4,5–tris–(phosphate)phosphatase photoaffinity probe, inositol IP3 analog with *p*–azidobenzoyl and biotinyl moieties, 399

Phosphate
masked derivs of anti–cancer agent araC, via *trans*–esterification, 607
oxygen exchange, catalysed by inositolmonophosphatase, 193

Phosphatidylinositol
specific phospholipase C, phosphate substrate for continuous spectrophoto–metric assay,hexadecyl–thiophosphoryl–1–*myo*–inositol, 615
specific phospholipase C, fluorescent sub– strate for assay, 4–(1–pyreno)butyl–phosphoryl–1–*myo*–inositol, 619

Phosphinic acids
inhibitors,3–hydroxy–3–methylglutaryl coenzyme A reductase, 151

Phosphonamidate
and phosphonamidate esters as HIV–1 protease inhibitors, 653

Phosphonate
difluoromethylene–, analog AZT 5'– triphosphate inhibition HIV–1 reverse transcriptase, 357

Phosphorothionates
myo–inositol–, biologically important, 239

Photoaffinity
probe, inositol IP3 analog with *p*–azidobenzoyl and biotinyl moieties, 399

Physostigmine
8–carba–, analog, optically active, acetylcholinesterase inhibitor, 47

Pilocarpine
2–oxazolidinone analogs, acetyl–choline–receptor muscarinic agonist, 147

Podophyllotoxin
bisaryl analogs, tubulin polymerization inhibited, 243

Polysaccharides
branching decasaccharide fragment, typelll group B *Streptococcus*, synthesis, 391
sialyl Le^x and derivs, recombinant fucosyltransferase synthesis, 425

Polyamines
inhibited biosynthesis, restricted rotation analogs decarboxyl–ated S–adenosyl– methionine, 267

Potassium
channel activator WAY–120,491, structure, 39
channel activators, hypertensive benzo– pyran–related, role for lipophilicity, 591

Potency
conformation–preference, GnRH analogs, NMR, 263

Pregn–4–en–3,20–dione
21–hydroxy,21–formyl and 21–carboxylic, biomimetic oxidation with chemical cytochrome P450 model systems, 601

Preuroporphyrinogen
biosynthesis by PBG deaminase, enzyme bound intermediates, 503

Prevention
3–alkyl–4–azetidinone human leukocyte elastase–mediated lung damage, 545

Prodrugs
cancer–, activated cephalosporin–oncolytic targeted delivery system, 21
chemoreversible–, ARA–C, synthesis, 745
combined–, antiviral and antibiotic compds,O–alkyl–5,5'–dinucleosi de phosphates, 527

Propanediol
(*R*)–and(*S*)–3–chloro–1,2–propanediol by stereospecific dehalogenating bacteria, prep (*R*)– and (*S*)–glycidol, 343

Prolyl endoptidase
in vitro and *in vivo* inhibitors, 585

Prostacylin
arene–fused analog, synthesis, 77
arene–fused analogs (2), related U68,215, triply–convergent syn–theses, 79
benzoindane–fused analog, homochiral triply–convergent synthesis, 73
homochiral 3,3–dimethyl–15–cyclohexyl prostacyclin analog, triply–copnvergent synthesis, 649

Prostanoids
amino–, pyridine containing, throm– boxane receptor antagonist/thrombox–ane synthase inhib– itors, synthesis and evaluation, 695
amino–, synthesis and evaluation as throm– boxane A2 receptor antagonists, 689

Protease
HIV–1 inhibitors, C2–symmetric and pseudosymmetric from D–arabitol, 219
HIV–1 inhibitors, phosphonamidates and phosphonamidate esters, 653
serine hydrophobic model, 353
stable industrial–, catalyzed peptide bond formation in organic solvent, 445

Proteins
beta–pleated sheet structures, affinity/ cleaving reagent, 519
kinase C, not inhibited by FKBP, identical? PKCl–2, 205
tyrosine kinase inhibitors, phenyl–hydrazones, 215
tyrosine kinase inhibitors, pyridine– containing stilbenes and amides, 211

Proteinase
serine inhibitors, midazo–[1,2–a]–piperazines, 69

Pyrazolo[3,4–d]pyrimidine
4,6–bis(methylthio), glycosylation with D–glucofuranosyl sugars, 249

4–(1–Pyreno)–butyl–phosphoryl–1 myo–inositol
fluorescent substrate for assay of phosphatidylinositol–specific phospholipase, 619

Pyridine
containing–amides and –stilbenes, protein–tyrosine kinase inhibitors 211
containing–aminoprostanoids thromboxane receptor antagonist/thromboxane synthase inhibitors, 695
containing sulphonamino acids, synthesis and evaluation thromboxane receptor antagonist synthase inhibitor, 699dihydropyridine mimics, Ca–channel blocker dihydro–pyrimidine, 291
dihydropyridine mimics, Ca–channel blocker dihydropyrimidine, 291

Pyrimidine
(+/–)–1'–aza–carbocyclic–pyrimid ine–2',3'–dideoxynucleoside analogs, anti HIV agents, 757
dihydro–, Ca–channel blockers, dihydropyridine mimics, 291
TIBO analog, potential HIV–1 inhibitor, 531

Pyrroles
tricyclic phenyl–, lactams, antitubulin agents, synthesis, 725

Quinazolinones
synthesis conformationally restricted analogs ketanserin and SGB–1534 antihypertensive agents, 571

Quinozalines
tricyclic–, ligands for strychnine–insensitive glycine site, 751

R68070
compds related to R68070, TXA2 *in vitro* receptor antagonist/ synthase activity, 703

Radicals
metal–, generated from species with metal– metal bonds, nicking of supercoiled DNA, 451

Radiolabelling
CP–96,345, non–peptide P antagonist, 129

Reagents
affinity/cleaving–, for beta–pleated sheet protein structures, 519

Receptors
5–HT1A, reaction C8–pure enantiomer derivs 20(dipropyl–amino)tetralin, 257
5–HT2–, anatogist activity 3–amino– methyltetralones, 717
active PAF antagonist, activity MK 287 (L–680,573), 327
adenosine A1–, high selectivity of iso– guanosine analogues, 481
agonist GABAA,
(±)–2–amino–2–thiazoline–4–et hanoic acid, 247
binding conformation of carboxyl side– chain, conformation–ally restricted thromboxane antagonist analogs, SQ 33,961, 465
binding, monocyclic endothelin analogs, activity–structure relationships, 33
insulin, autophosphorylation site corresponding triphosphorylated peptide, conformational comparison non–phosphorylated analog, 299
ligands, DA–ergic activity, catechol bioisosteres, 403
NHDA and AMPA–, strychnine–insensitive glycine site, tri– cyclic quinoxaline ligands, 751
NMDA–, glutamate antagonist, conformationally–restricted 3(*S*)–phosphono–acetyl–2(*R*)–pi peridinecarboxylic acid, 441
NMDA–, glycine–site antagonists, design, synthesis and mol–ecular modeling of 3–acyl–amino–2–carboxyindole, 455
thromboxane A2 antagonists , syn–, thesis and evaluation of amino–prostan– oids, 689,
thromboxane–, anatonist/ thromboxane synthase inhibitor, pyridine containing amino–prostanoids, 695
thromboxane–, antagonist/ synthase inhibitor, pyridine containing sulphonamido acids, 699
TXA2, *in vitro* antagonist/synthase inhibitor activity compds related to R68070, 703

Reductase
5α–, inhibition by 3–nitrosteroids, mechanism and activity, 27
HMG CoA, substrate–based inhibitors, 61

Reduction
baker's yeast–, in D2O, use isotopical labelling N–acetylcysteamine, 223
microbial–, ethyl 4,4,4–trifluoro–3–hydroxy butanoate, prep enantiomers, 675

Regioselection
glycosylation, 4,6–bis–(methylthio)–pyrazolo–[3,4–*d*]p yrimidine with D–gluco furanosyl sugars, 249
synthesis 8,9–dichloro–2,3,4,5–tetrahydro–1*H*–2–benzazepine (LY134046), phenylethano–amine N–methyltransferase inhibitor, 59

Regiospecificity
bio–oxidative conversion, version, 5–thio to 5–oxo in 5,11–dithiopyrrolo–[1,4]benzodiazepine antibiotics, 159

Resolution
and synthesis, 7–fluoro tryptophans, 477

Rhazinilam
analog tricyclic phenylpyrrole lactams, antitubulin agents, synthesis, 725

Rhodophyceae
cultures, 5α–androstane–3,17–dione bioconversion, 673

Rotation
restricted–, analogs decarboxylated S–adenosylmethion—ine inhibitors, polyamine bio synthesis, 267

Saccharins
4–alkyl/aryl substit–, synthesis, 733

Satratoxin
macrocyclic diester, synthesis structure–activity, 361

SCH 42427
SM 9164, antifungal agent 349

Semicarbazide
deriv, analog CC–1065 alkylation subunit 55

Serine
galactopyranosyl–L–, stereospecific chemoenzymatic synthesis, 197
protease model, recognition hydrophobic substrates, 353
proteinase inhibitors, imidazo[1,2–*a*]piperazines, 69

Sesterterpenes
linear–, from *Thorecta horridus* with inflammatory activity, 639

Sialyl Le^x
and derivs, fucosyl–transferase recomb–inant synthesis, 425

SGB–1534
and ketanserin antihypertensive agents, synthesis conformationally restricted analogues via quinazolinones, 571

Siderophore
growth promoting activity compds for *E.coli*, 513

Spectroscopy
^{11}B NMR, aryl boronic acid bound to chymotrypsin and subtilisin, 9
FT–IR evidence chloramphenicol intramolecular H–bond, 253

Squalene
epoxidase, 26–hydroxysqualene and derivs, substrates and inhibitors, 227
oxido–, pig liver and yeast cyclases, behaviour epoxy–squalene analogs with 18 19*Z* or *E* C, C double bond, 365
SQ 33,961, conformationally restricted thromboxane antagonist analogs, receptor binding conformation of carboxyl side–chain, 465
SQ 33,961, thromboxane long–acting antagonist, 461

Stereochemistry
spermidine–based tricatecholate compd and carbacephalo–sporin conjugate, synthesis, 513
stereospecific chemoenzymatic synthesis galactopyranosyl–L–serine, 197

Stereospecificity
stereochemistry at C12 and C14 ionomycin, 535

Steric course
epoxidation, hydroxyl ation, cytochrome P–450 oxidation 1–methylcyclohexene, 121

Steroids
3–nitrosteroids, 5α–reductase inhibition, mechanism and activity, 27

Streptococcus
capsular polysaccharide, type III group B, synthesis, branching decasaccharide fragment, 391

Streptomyces griseochromogenes
cellfree extract, conversion demethylblasticidin S–adenosyl–L–[^{14}CH3]methionine to blasticidin S, 497

Structure activity
2–oxazolidinone analog, pilocarpine, acetyl–choline–receptor muscarinic agonist, 147
4–alkyl/aryl substit saccharins, synthesis, 733
relationships, monocyclic endothelin analogs, 33
trichothecene satratoxin, 361

Structures
avermectin analogs spacer between aglycone and disaccharide, 369
C2–and pseudo–symmetric HIV–1 protease inhibitors from D–arabitol and D–mammitol, 219
characterization, WAY–120,491, K–channel activator, 39
homologs, TXA2 receptor antagonists, requirements inter–action with TXA2 receptors, 173
influences, styryl– based inhibitors, epidermal growth factor receptor and tyrosine–specific protein kinases, 165
partial, bouvardin, deoxy–bouvardin, and RA–I–RA–VII, pharmacophore reassignment, 313
requirements, binding colchicine analogs to tubulin, role of C–10 substituent, 471
S1' subsite of carboxy–peptidase A, 317

Substrates
26–hydroxysqualene and derivs for squalene epoxidase, 227
D– and L–*myo*– inositol 1–phos–phorothioate for inositol monophosphatase, 17
inhibitors HMG CoA reductase–II, 161
inhibitors, HMG CoA reductase synthesis, 61

Substituents
C–10–, role in structural require–ments, tubulin binding colchicine analogs, 471

Subtilisin
bound aryl boronic acid, ^{11}B NMR, 9

Sugars
peptide conjugate, approach synthesis *Neisseria meningitidis* vaccine, 303

Sulfonamides
2–substit–1,3,5–thiadiazole–5–sulf onamide, water–soluble carbonic anhydrase inhibitor, 407
pyridine containing sulphonamido acids, synthesis and evalua tion, thromboxane receptor antagonist/synthase inhibitor, 699

Surfactants
perfluorinated non– ionic telomeric amphiphiles with trishydroxymethyl groups, 103

Sulfur
role in cephalosporin biosynthesis, 421

Target
targeted delivery system, activated cephalosporin–oncolytic prodrug, cancer, 21

Terfenadine
R and *S* optical isomers, anti–histamine activity, 387

Tetrahydroacridine
deriv, optimizing log *P*, log *D* and pKa, 411

Tetrahydrofurans
trans–diaryl–, MK 287 (L–680,573) active PAF receptor, antagonist activity, 327

4,5,6,7–Tetrahydrobenzothiazole
dopamine agonists, low stereo–selectivity interaction dopamine receptors, 189

Tetrahydropteroylpolyglutamates
N–formyl deriv, 155

Tetralin
20(dipropylamino)tetra–lin, C8–pure enantiomeric derivs, reactions 5–HT$_{1A}$ receptors, 257

Tetrazolinium salts
inner salt MTS and related analogs of MTT, reducing to purple water–soluble formazan cell viability indicators, 611

Thermostability
oligothymidylates with sulfur modified thymidine, effect of thiation of pyrimidine ring, 523

1,3,5–Thiadiazole–5–sulfonamides
2–substit, water– soluble carbonic anhydrase inhibitors, 407

Thiazesim hydrochloride
R–(–)–, enantioselective chemoenzymatic synthesis, 383t

Thiazoline
⟨±⟩–2–amino–2–thiazo–line–4–eth anoic acid GABAA receptor agonist, 247

Thiols
conversion to disulfides, baker's yeast catalysed oxidative coupling, 507 BIOM–11

Thiophosphate
substrate for continuous spectrophotometric assay phos–phatidylinositol–specific phospholipase C, hexadecylthio–phosphoryl–1–*myo*–inositol, 615

Thorecta horridus
linear sesterterpenes with inflammatory activity, 639

Threonine
optically active 4,4–di–fluoro–deriv, antitumor potency, 271

Thromboxane
A2, receptor antagonist synthesis and evaluation of amino– prostanoids, 689

long–acting antagonist, interphenylene 7–oxa–bicyclo[2.2.1]–heptanes, SQ 33,961, 461
receptor antagonists, structural homologs interaction with TXA2 receptors, 173
receptor antagonist /synthase inhibitor, pyridine containing sulphonamido acids, 699
receptor antagonist /thromboxane synthase inhibitor, pyridine containing amino–prostanoids, 695
TXA2, *in vitro* receptor antagonist /synthase inhibitor activity compds related to R68070, 703

Thymidine
1'–N–replaced carbocyclic analogs, anti–AIDS agents, 287

Transcriptase
HIV–1 reverse inhibition, AZT 5'–triphosphate difluoro–methylene phosphonate analog, 357

Transport
enhanced through cooperativity circulating system, 87

Trichothecene
satratoxin macrocyclic part, partial synthesis structure–activity, 361

Tricyclic ring systems
substituted 5–amino–8–phenyl–3H,6H–1,4,5a,8a–tetra azaacenaphthalen–3–ones, for improvement of cognition, 435

Triply convergent synthesis
arene–fused prostacyclin analogs related U68,215, 79
homochiral 3,3–dimethyl–15–cyclohexyl prostacyclin analog, 649
homochiral benzoindane–fused prostacyclin analog, 73
two homochiral cyclopent–[*a*]indene carbacyclin analogs, 83

Tryptanosoma cruzi
growth inhibitors, activity of juvenile hormone analogs, 679

Tryptophane
7–fluorotryptophanes, resolution and synthesis, 477
tryptophanylphenethylamides, stability to acid and alkali, 169

Tyrosine
specific protein kinase styryl–based inhibitors, activity, 165

Tuberculin
isomer, effect, activity 4–amino–1–(β–D–ribofuranosyl)–pyrrolo[2,3–*d*]pyridazine, 111

Tubulin
binding colchicine analogs, structural requirements, role of C–10 substituent, 471
binding conformationally restricted bis–aryl compds, 243

Vaccine
Neisseria meningitidis, sugar–peptide conjugate, approach synthesis, 303

Vasoconstriction
monocyclic endothelin analogs, activity structure relation–ships, 33

Viruses
anti–human rhinovirus 14, activity and synthesis disoxaril analogs, 575

WAY–120,491
K–channel activator, structure, 39

Z–cyclohexyl–and Z–indolinyl–prolinal
in vitro and *in vivo* inhibitors of prolyl endopeptidase, 585

Author Index 1991

Acton J. see Sahoo S.P. 327

Akers J. see Middlemiss D. 711

Alazard J.–P. Millet–Paillusson C. Boye O. Guenard D. Chiaroni A. Riche C. and **Thal C.** Synthesis of tricyclic phenylpyrrole lac– tams, new models of antitubulin agents 725

Albers M.W. Liu J. Wilkinson S.E. Wadsworth J. Perez–Sala D. Rando R.R. Nixon J.S. and **Schreiber S.L.** FKBP, thought to be identical to PKC1–2, does not inhibit protein kinase C 205

Alberts A.W. see Sahoo S.P. 327

Andersen N.H. and **Hammen P.K.** A conformation–preference/potenc y correlation for GnRH analogs: NMR evidence 263

Andrade F.A.C. see Andrade M.A.C. 373

Andrade M.A.C. Andrade F.A.C. and **Phillips R.S.** Temperature and DMSO increase the enantioselectivity of hydrolysis of methyl alkyl dimethyl–malonates catalyzed by pig liver esterase 373

Antonakis K. see Bessodes M. 361

Antonakis K. see Herscovici J. 395

Antonakis K. see Herscovici J. 721

Aplin R.T. Bladwin J.E. Pichon C. Roessner C.A. Scott A.I. Schofield C.J. Stolowich N.J. and **Warren M.J.** Observation of enzyme bound intermediates in the biosynthesis of preuroporphyrinogen by PBG deaminase 503

Artico M. see Massa S. 575

Ashe B.M. see Hagmann W.K. 545

Ashley J.A. see McLeod D.A. 653

Attal S. see Cantacuzene D. 197

Atwal K.S. and **Moreland S.** Dihydropyrimidine calcium channel blockers–V. Bicyclic dihydropyrimidines as potent mimics of dihydropyridines 291

Avasthi K. Deo K. Garg N. and **Bhakuni D.S.** Regioseclectivity of glycosylation reaction of 4,6–bis(methyl–thio)–pyrazolo[3,4–*d*]pyrimidine with D–xylofuranosyl– and D–glucofuranosyl sugars 249

Avila L.Z. Draths K.M. and **Frost J.W.** Metabolites associated with organophosphonate C–P bond cleavage: chemical synthesis and microbial degradation of [^{32}P]–ethylphosphon– ic acid 51

Bach T.J. see Sahoo S.P. 327

Bai M. Xiao X. and **Prestwich G.D.** 26–Hydroxysqualene and derivatives: substrates and inhibitors for squalene epoxidase 227

Baker G.R. Billington D.C. and **Gani D.** Chemical and enzymic syntheses of D– and L–*myo*–inosi–tol1–phosphorothio– ate substrates for inositol monophos– phatase: D–glucose 6–phosphorothioate is not a substrate for inositol synthase 17

Baker G.R. and **Gani D.** Inositol dependent phosphate–oxygen ligand exchange catalysed by inositol monophosphatase 193

Bakker A.V. Daffeh J. Jung S. Vincent L.A. Nagel A.A. Spencer R.W. Vinick F.J. and **Faraci W.S.** Novel *in vitro* and *in vivo* inhibitors of prolyl endopeptidase 585

Baldwin J.E. Goh K.–C. Wood M.E. Schofield C.J. Cooper R.D.G. and **Huffman G.W.** The role of sulphur in cephalosporin biosynthesis 421

Baldwin J.E. Claridge T.D.W. Derome A.E. Schofield C.J. and **Smith B.D.** ^{11}B NMR Studies of an aryl boronic acid bound to chymo– trypsin and subtilisin 9

Balzarini J. see Hebel D. 357

Barltrop J.A. Owen T.C. Cory A.H. and **Cory J.G.** 5–(3–Carboxymethoxyphenyl)–2 –(4,5–dimethylthiazolyl)–3– (4–sulfophenyl)tetrazolium, inner salt (MTS) and related analogs of 3–(4,5–dimethylthiazolyl)–2,5–diphenyl tetrazoli um bromide (MTT) reducing to purple water–soluble for– mazans as cell– viability indicators 611

Baron B.M. see Salituro F.G. 455

Baron B.M. see Whitten J.P. 441

Bartus R.T. see Levin J.I. 435

Bay S. see Cantacuzene D. 197

Beer B. see Levin J.I. 435

Bell M.R. see Subramanyam C. 733

Belley M. see Prasit P. 645

Bellucci G. Chiappe C. Marioni F. Gervasi P.G. and **Lippi A.** The cytochrome P–450 catalyzed oxidation of 1–me– thylcyclohexene. Competition between hydroxylation and epoxidation and absolute stereo– chemistry of the epoxidation 121

Benigni D.A. see Mansuri M.M. 65

Bennani–Baiti M.I. see Herscovici

J. 395

Bennani–Baiti M.I. see Herscovici J. 721

Berglund R.A. Braish T.F. Jakubowski J.A. and **Fuchs P.L.** Triply–convergent synthesis of a homochiral 3,3–dimethyl, 15–cy– clohexyl prostacyclin analog 649

Bernier J.L. see Chan P. 277

Bertsch B. see Yu M.J. 107

Bessodes M. Shamsazar J. Antonakis K. Lafarge–Frayssinet C. and **Frayssinet C.** Studies on the macrocyclic part of the trichothecene satratoxin: partial synthesis and structure–activity relationship 361

Besterman J.M. see Boger D.L. 115

Bey P. see Flynn G.A. 309

Bhakuni D.S. see Avasthi K. 249

Biftu T. see Sahoo S.P. 327

Billington D.C. see Baker G.R. 17

Blackburn G.M. see Howson W. 501

Blackburn G.M. see Jayaweera G.D.S.A. 407

Bladwin J.E. see Aplin R.T. 503

Blizzard T. Margiatto G. Linn B. Mrozik H. and **Fisher M.** Avermectin analogs with a spacer be– tween the aglycone and the disaccharide 369

Boehm C. see Chenera B. 219

Boger D.L. Ishizaki T. Sakya S.M. Munk S.A. Kitos P.A. Jin Q. and **Besterman J.M.** Synthesis and preliminary evalu– ation of (+)–CBI– indole2: an enhanced functional analog of (+)–CC–1065 115

Boger D.L. Myers J.B. Yohannes D. Kitos P.A. Suntornwat O. and **Kitos J.C.** Evaluation of bouvardin, deoxy– bouvardin, and RA–1–RA–VII partial structures: reassignment of the pharmacophore 313

Boger D.L. Ishizaki T. Zarrinmayeh H. Kitos P.A. and **Suntornwat O.** A potent, simple derivative of an analog of the CC–1065 alkylation subunit 55

Bohan C. see Soll R.M. 591

Bolen J.B. see Burke T.R.,Jr. 165

Bonney R.J. see Hagmann W.K. 545

Boons G.J.P.H. Hoogerhout P. Poolman J.T. van der Marel G.A. and **van Boom J.H.** Preparation of a well–defined sugar–peptide con– jugate: a possible approach to a synthetic vaccine against *Neisseria meningitidis* 303

Bordner J. see Lowe J.A.,III 129

Botti C.M. see Misra R.N. 295

Boye O. see Alazard J.–P. 725

Braish T.F. see Berglund R.A. 649

Braish T.F. see Neville C.R.,Jr. 77

Brankovan V. see Mansuri M.M. 65

Brause K.A. see Hagmann W.K. 545

Brinkworth R.I. see McLeod D.A. 653

Bristol J.A. see Cody W.L. 415

Broekman M. see Howson W. 501

Brown B.R. see Misra R.N. 461

Brown B.R. see Misra R.N. 465

Browne E.N.C. see Quagliato D.A. 39

Bruce J.L. see Nair V. 481

Bugianesi R.L. see Sahoo S.P. 327

Burguete M.I. see Luis S.V. 87

Burke T.R.,Jr. Li Z.–H. Bolen J.B. and **Marquez V.E.** Structural influences of styryl–based inhibitors on epi–dermal growth factor receptor and $p56^{lck}$ tyrosine–specific protein kinases 165

Burkholder T.P. see Flynn G.A. 309

Bustos D. see Jung M. 741

Cain W.T. see Levin J.I. 435

Calas B. see Chavanieu A. 299

Calleja J.M. see Loza M. 717

Campbell I.B. Collington E.W. Finch H. Hallett P. Hayes R. Lumley P. Mills K. Wallis C.J. and **White B.P.** Synthesis and phar– macological evalu– ation of novel amino–prostanoids: potent and orally effective throm– boxane A2 receptor antagonists 689

Campbell I.B. Collington E.W. Finch H. Hayes R. Lumley P. Mills K. Robertson G.M. Wharton K. and **Watts I.S.** Synthesis and pharmacological evaluation of com– bined thromboxane receptor antagonist/ thromboxane syn–thase inhibitors: pyridine–containing amino–prostanoids 695

Campbell I.B. Collington E.W. Finch H. Hayes R. Lumley P. Mills K. Pike N.B. Robertson G.M. and **Watts I.S.** Synthesis and phar– macological evalu–ation of combined thromboxane receptor antagonist/synthase inhibitors: pyridine–containing sulphonamido acids 699

Campbell M.M. Mickel S.J. and **Singh G.** ()–2–Amino–2–thiazoline–4–eth anoic acid; a novel, specific GABAA receptor agonist 247

Cantacuzene D. Attal S. and **Bay S.** Stereospecific chemoenzymatic synthesis of galac– topyranosyl–L–serine 197

Caprathe B.W. see Jaen J.C. 189

Caprathe B.W. see Jaen J.C. 539

Cardwell K. see Middlemiss D. 711

Castro M.E. see Loza M. 717

Chabala J.C. see Sahoo S.P. 327

Chae Y.B. see Lee Y.H. 287

Chan P. Cotelle P. Cotelle N. Bernier J.L. and **Henichart J.P.** Glutathione peroxidase: redox chemistry of active site model peptides 277

Chauhan S.M.S. and **Ray P.C.** Biomimetic oxidation of 21–hy–droxy, 21–formyl and 21–carboxylic pregn–4–en–3,20–dione with chemical cytochrome P450 model systems 601

Chavanieu A. Naharisoa H. Heitz F. Calas B. and **Grigorescu F.** Synthesis of a tri–phosphorylated peptide corres– ponding to the major autophosphorylation site in the insulin receptor: conforma–tional comparison with its non–phos– phorylated analogue 299

Chen Q.–Z. see Taschner M.J. 535

Chen S.–T. Hsiao S.–C. and **Wang**

K.–T. Stable iondustrial protease catalyzed peptide bond formation in organic solvent 445

Chen Y.L. and **Hedberg K.** Total synthesis of an optically active 8– carba–physostigmine analog: a potent acetylcholinesterase inhibitor 47

Chenera B. Boehm C. and **Dreyer G.B.** Synthesis of C2–symmetric and pseudosymmetric HIV–1 protease inhibitors from D–mannitol and D–arabitol 219

Chern J.–W. Shiau C.–Y. and **Lu G.–Y.** Studies on quinazolinones–III. Novel and efficient route to the synthesis of conformationally restricted analogues of ketanserin and SGB–1534 as antihypertensive agents 571

Chiappe C. see Bellucci G. 121

Chiaroni A. see Alazard J.–P. 725

Chmurny G.N. see Fitzhugh A.L. 155

Choay J. see Duchaussoy P. 95

Choay J. see Duchaussoy P. 99

Christenson J.G. see Wei C.–C. 43

Chrystal E.J.T. see Field R.A. 667

Chu F.–Y. see Wu S.–H. 339

Ciosek C.P., Jr. see Misra R.N. 295

Ciosek C.P.,Jr. see Gordon E.M. 161

Ciosek C.P.,Jr. see Gordon E.M. 61

Claridge T.D.W. see Baldwin J.E. 9

Clark K.L. see Middlemiss D. 711

Cody W.L. Giordani A.B. Werness S. Reily M.D. Bristol J.A. Zhu G. and **Dudley D.T.** Analysis of rat amylin amide from commercial sources: identification of a mercury complex 415

Collington E.W. see Campbell I.B. 689

Collington E.W. see Campbell I.B. 695

Collington E.W. see Campbell I.B. 699

Combs D.W. Rampulla M.S. and **Falotico R.** 2–Aryl–1,2–dihydro–6,7–dimeth oxyquinazoline–3–o xides with positive inotropic activity 133

Cooper R.D.G. see Baldwin J.E. 421

Coote S. see Middlemiss D. 711

Corelli F. see Massa S. 575

Corraz A.J. see Wei C.–C. 43

Cortizo L. see Liu Y. 257

Cortizo L. see Loza M. 717

Cory A.H. see Barltrop J.A. 611

Cory J.G. see Barltrop J.A. 611

Costero A.M. see Luis S.C. 87

Cotelle N. see Chan P. 277

Cotelle P. see Chan P. 277

Coughenour L.L. see Hobbs S.H. 147

Cube R.V. see Whitten J.P. 441

Cushman M. Nagarathnam D. Gopal D. and **Geahlen R.L.** Synthesis and evaluation of new protein–tyrosine kinase inhibitors–I. Pyridine–containing stilbenes and amides 211

Cushman M. Nagarathnam D. Gopal D. and **Geahlen R.L.** Synthesis and evaluation of new protein–tyrosine kinase inhibitors–II. Phenylhydrazones 215

Daffeh J. see Bakker A.V. 585

Dahlgren M.E. see Hagmann W.K. 545

Davenport T.W. see Jackson P.F. 751

Davies P. see Hagmann W.K. 545

Davies P. see Sahoo S.P. 327

Davis B.M. see Han S.Y. 579

Davis R.E. see Hobbs S.H. 147

de Ceballos M.L. see Loza M. 717

De Clercq E. see Hebel D. 357

Dean R.L.,III. see Levin J.I. 435

Dean W.D. see Levin J.I. 435

Deininger D.D. see Soll R.M. 591

Della Greca M. Lanzetta R. Mangoni L. Monaco P. and **Previtera L.** A bioactive benzo– indenone from *Eichhornia crassipes* Solms 599

Dellea P.S. see Hagmann W.K. 545

Demeter D.A. see Salituro F.G. 455

Deo K. see Avasthi K. 249

Derome A.E. see Baldwin J.E. 9

Derrien M. see Duchaussoy P. 95

Trager S.F. see Jayaweera G.D.S.A. 407

Desai M.C. Thadeio P.F. Lipinski C.A. Liston D.R. Spencer R.W. and **Williams I.H.** Physical para– meters for brain uptake: optimizing log *P*, log *D* and p*K*a of THA 411

Devine K.G. see McGuigan C. 729

Di Rosa M. see Fattorusso E. 639

Dike S.Y. Ner D.H. and **Kumar A.** A new enantioselective chemoenzymatic synthesis of *R*–(–)Thiazesim hydrochloride 383

Dillon M.P. Hayes M.A. Simpson T.J. and **Sweeney J.B.** The synthesis of isotopically labelled N–acetylcysteamine thioesters utilising a baker's yeast re– duction in D2O 223

Djuric S.W. Miyashiro J.M. Penning T.D. Keith R.H. Villani–Price D. and **Tsai B.–S.** Enantioselective total synthesis and phar– macologic profile of 12–deoxy–12(*S*)–methyl Leukotriene B4 179

Doebber T.W. see Sahoo S.P. 327

Doherty J.B. see Hagmann W.K. 545

Dolak T.M. see Soll R.M. 591

Dollings P.J. see Soll R.M. 591

Dorn C.P. see Hagmann W.K. 545

Douglas K.A. Zormeier M.M. Marcolina L.M. and **Woster P.M.** Restricted rotation analogs of decarboxylated S–adenosylmeth– ionine as inhibitors of polyamine biosyn– thesis 267

Dowle M.D. see Middlemiss D. 711

Draths K.M. see Avila L.Z. 51

Dreef C.E. Mayr G.W. Jansze J.–P. Roelen H.C.P.F. van der Marel G.A. and **van Boom J.H.** An expeditious synthesis of biologically im– portant *myo*–inositol phosphorothioates 239

Drew G.M. see Middlemiss D. 711

Dreyer G.B. Garvie C.T. Metcalf

B.W. Meek T.D. and Mayer R.J. Phosphinic acid inhibitors of 3–hy– droxy–3–methylglutaryl–coenzy me A reductase 151

Dreyer G.B. see Chenera B. 219

Drozda S.E. see Lowe J.A.,III 129

Duchaussoy P. Jaurand G. Derrien M. Petitou M. and **Choay J.** A new highly potent, heparin–like penta– saccharide fragment containing a glucose residue instead of a glucosamine 95

Duchaussoy P. Lei P.S. Petitou M. Sinay P. Lormeau J.C. and **Choay J.** The first total synthesis of the antithrombin III binding site of porcine mucosa heparin 99

Dudley D.T. see Cody W.L. 415

Dudley D.T. see Hobbs S.H. 147

Dumas D.P. Ichikawa Y. Wong C.–H. Lowe J.B. and **Nair R.P.** Enzymatic synthesis of sialyl Le^x and derivatives based on a recom– binant fucosyl– transferase 425

Dusza J.P. see Levin J.I. 435

Eldred C.D. see Middlemiss D. 711

ElSohly H.N. see Jung M. 741

Engebrecht J.R. see Misra R.N. 295

Epstein J.W. see Levin J.I. 435

Erhardt S. see Stoss P. 629

Evans J.F. see Prasit P. 645

Falotico R. see Combs D.W. 133

Faraci W.S. see Bakker A.V. 585

Farina V. see Mansuri M.M. 65

Fasbender A.J. see Nair V. 481

Fattorusso E. Lanzotti V. Magno S. Mayol L. Di Rosa M. and **Ialenti A.** Linear sesterterpenes from the Caribbean sponge *Thorecta horridus* with inflammatory activity 639

Field R.A. Haines A.H. and **Chrystal E.J.T.** The interaction of anhydroalditols with sweet–almond β–glucosidase and *Escherichia coli* β–galactosidase: implications for the design of potent glycosidase inhibitors 667

Finch H. see Campbell I.B. 689

Finch H. see Campbell I.B. 695

Finch H. see Campbell I.B. 699

Finke P.E. see Hagmann W.K. 545

Fiorentino A. Pinto G. Pollio A. and **Previtera L.** Biotransformation of 5α–androstane–3,17–dione by microalgal cultures 673

Fisher M. see Blizzard T. 369

Fitzhugh A.L. Chmurny G.N. and **Klose J.R.** A new and facile synthetic to N^5–formyl tetra– hydropteroylpoly–L–glutamates 155

Fitzhugh A.L. Chloramphenicol: high–dilution FT–IR evidence for an intramolecular hydrogen bond 253

Fletcher D.S. see Hagmann W.K. 545

Flynn G.A. Burkholder T.P. Huber E.W. and **Bey P.** An acyliminium ion route to *cis* and *trans* 'anti' Phe–Gly dipeptide mimetics 309

Fontenla J.A. see Loza M. 717

Forrow S.M. see Lee M. 595

Francisco G.D. see Levin J.I. 435

Frayssinet C. see Bessodes M. 361

Frayssinet C. see Herscovici J. 395

Frayssinet C. see Herscovici J. 721

Frost J.W. see Avila L.Z. 51

Fuchs P.L. see Berglund R.A. 649

Fuchs P.L. see Hardinger S.A. 73

Fuchs P.L. see Hardinger S.A. 79

Fuchs P.L. see Nevill C.R.,Jr. 83

Fuchs P.L. see Neville C.R.,Jr. 77

Fuchs V. see Skiles J.W. 69

Fuji K. see Ishikawa T. 523

Ganguly A.K. see Girijavallabhan V.M. 349

Gani D. see Baker G.R. 17

Gani D. see Baker G.R. 193

Garg N. see Avasthi K. 249

Garvie C.T. see Dreyer G.B. 151

Gauthier J.Y. see Prasit P. 645

Gavina F. see Luis S.V. 87

Geahlen R.L. see Cushman M. 211

Geahlen R.L. see Cushman M. 215

Geen G.R. Harnden M.R. and **Parratt M.J.** Synthesis of 9–[2,2–bis(hydroxymethyl)cyclo prop–1–yl)guanine as a po– tential antiviral agent 347

Georg G.I. Guan X. and **Kant J.** Asymmetric synthesis of α–alkylated α–amino acids: azepane–2–carboxylic acids 125

Gervasi P.G. see Bellucci G. 121

Giordani A.B. see Cody W.L. 415

Girijavallabhan V.M. Ganguly A.K. Pinto P.A. and **Sarre O.Z.** Synthesis of the antifungal agent Sch 42427 (SM 9164) 349

Girotra N.N. see Sahoo S.P. 327

Gmeiner W.H. Luo W. Pon R.T. and **Lown J.W.** Development of an efficient oligo– nucleotide deriv– atization protocol 487

Goh K.–C. see Baldwin J.E. 421

Goldenberg H.J. see Misra R.N. 461

Gopal D. see Cushman M. 211

Gopal D. see Cushman M. 215

Gordon E.M. Pluscec J. and **Ciosek C.P.,Jr.** Synthesis of subsrate–based inhibitors of HMG CoA reductase–II 161

Gordon E.M. Pluscec J. and **Ciosek C.P.,Jr.** Synthesis of substrate–based inhibitors of HMG CoA reductase 61

Gordon E.M. see Patel D.V. 509

Gould S.J. see Guo J. 497

Graham D.W. see Sahoo S.P. 327

Grigorescu F. see Chavanieu A. 299

Gros E.G. see Rodriguez J.B. 679

Grunewald G.L. and **Paradkar V.M.** A regioselective syn– thesis of 8,9–

dichloro–2,3,4,5–tetrahydro–1*H*–2–benzazepin e (LY134046), a potent phenyl– ethanolamine *N*–methyltransferase inhibitor 59

Guadino J. see Pozsgay V. 391

Guan X. see Georg G.I. 125

Guenard D. see Alazard J.–P. 725

Guerrero A. and **Raja F.** Preparation of both enantiomers of ethyl 4,4,4–trifluoro–3–hydroxy butanoate by enantioselective microbial reduction 675

Guo J. and **Gould S.J.** Biosynthesis of blasticidin S. Cell–free demon– stration of N–methyl–ation as the last step 497

Hacksell U. see Liu Y. 257

Haeggstrom J.Z. see Yuan W. 551

Haga J. see Yamazaki T. 271

Hagmann W.K. Shah S.K. Dorn C.P. O'Grady L.A. Hale J.J. Finke P.E. Thompson K.R. Brause K.A. Ashe B.M. Weston H. Dahlgren M.E. Maycock A.L. Dellea P.S. Hand K.M. Osinga D.G. Bonney R.J. Davies P. Fletcher D.S. and **Doherty J.B.** Prevention of human leukocyte elastase– mediated lung damage by 3–alkyl– 4–azetidinones 545

Hahn K.M. Humphreys W.G. Helms A.M. Hastie S.B. and **Macdonald T.L.** Structural requirements for the binding of colchicine analogs to tubulin: the role of the C–10 substitutent 471

Haines A.H. see Field R.A. 667

Hale J.J. see Hagmann W.K. 545

Hallett P. see Campbell I.B. 689

Hamblett J. see Middlemiss D. 711

Hammen P.K. see Andersen N.H. 263

Han S.Y. Mayer S.C. Schweiger E.J. Davis B.M. and **Joullie M.M.** Synthesis and biological activity of galanthamine derivatives as acetylcholinesterase (AChE) inhibitors 579

Hand K.M. see Hagmann W.K. 545

Hardinger S.A. Jakubowski J.A. and **Fuchs P.L.** Triply–convergent total synthesis of a homochiral benzo– indane–fused prostacyclin analog 73

Hardinger S.A. Jakubowski J.A. and **Fuchs P.L.** Triply–convergent syntheses of two homochiral arene– fused prostacyclin analogs related to U68,215 79

Harnden M.R. see Geen G.R. 347

Harris D.N. see Misra R.N. 461

Harris D.N. see Misra R.N. 465

Hartley J.A. see Lee M. 595

Haslanger M.F. see Misra R.N. 295

Hastie S.B. see Hahn K.M. 471

Hayes M.A. see Dillon M.P. 223

Hayes R. see Campbell I.B. 689

Hayes R. see Campbell I.B. 695

Hayes R. see Campbell I.B. 699

Hebel D. Kirk K.L. Kinjo J. Kovacs T. Lesiak K. Balzarini J. De Clercq E. and **Torrence P.F.** Synthesis of a difluoromethylenephosphonate analogue of AZT 5'–triphosphate and its inhibition of HIV–1 reverse transcriptase 357

Hedberg A. see Hunt J.T. 33

Hedberg K. see Chen Y.L. 47

Heffner T.G. see Jaen J.C. 189

Heffner T.G. see Jaen J.C. 539

Heitz F. see Chavanieu A. 299

Helms A.M. see Hahn K.M. 471

Hendrickson E.K. Johnson J.L. and **Hendrickson H.S.** A thiophosphate substrate for a continuous spec– trophotometric assay of phosphatidyl–inositol–specific phospholipase C: hexadecylthiophosphoryl–1–*myo*–inositol 615

Hendrickson E.K. Johnson J.L. and **Hendrickson H.S.** A fluorescent substrate for the assay of phosphatidylinositol–specific phospho– lipase C:4–(1–pyreno)butylphosphoryl–1–*myo*–inositol 619

Hendrickson H.S. see Hendrickson E.K. 615

Hendrickson H.S. see Hendrickson E.K. 619

Henichart J.P. see Chan P. 277

Herscovici J. Bennani–Baiti M.I. Frayssinet C. and **Antonakis K.** Keto C–glycosides. A new class of antitumor compounds 395

Herscovici J. Bennani–Baiti M.I. Montserret R. Frayssinet C. and **Antonakis K.** Design, synthesis and cytotoxic evaluation of keto–C–glycoside fatty acid conjugates 721

Higton A.M. see Jones R.C.F. 353

Hilditch A. see Middlemiss D. 711

Hills J.M. see Howson W. 501

Hirata M. see Watanabe Y. 399

Hirst G.C. see Middlemiss D. 711

Ho C.Y. and **Kukla M.J.** Synthesis of the pyrimidine analog of 4,5,6,7–tetrahydroimidazo[4,5,1–*jk*][1,4]benzodiazepin–2–(1*H*)one (TIBO); potential for HIV–1 inhibition 531

Ho P.P.K. see Yu M.J. 107

Hobbs S.H. Johnson S.J. Kesten S.R. Pavia M.R. Davis R.E. Schwarz R.D. Coughenour L.L. Myers S.L. Dudley D.T. and **Moos W.H.** Cholinergic agents: 2–oxazolidinone analogues of the acetylcholine–receptor muscarinic agonist pilocarpine 147

Metcalf B.W. and **Wier P.J.** Inhibition of steroid 5α–reductase by 3–nitrosteroids: synthesis, mechanism of inhibition, and *in vivo* activity 27

Honek J.F. see Houston M.E.,Kr. 623

Hoogerhout P. see Boons G.J.P.H. 303

Horwell D.C. Ratcliffe G. and **Roberts E.** Stabilities of tryptophanylphenethylamides to acid and alkaline conditions 169

Houston M.E.,Kr. Vander Jagt D.L. and **Honek J.F.** Synthesis and biological activity of fluorinated inter– mediates of the methionine salvage pathway 623

Howson W. Hills J.M. Blackburn G.M. and **Broekman M.** Synthesis and biological evaluation of 3–amino–2–(4–chlorophenyl)

1,1,–difluoropropyl phosphonic acid 501

Hsiao S.–C. see Chen S.–T. 445

Huber E.W. see Flynn G.A. 309

Huber S.K. Werbovetz K.A. Obaza–Nutaitis J. Lehnert E.K. and **Macdonald T.L.** Tubulin binding of conformationally restricted bis–aryl compounds 243

Huffman G.W. see Baldwin J.E. 421

Humber L.G. see Quagliato D.A. 39

Humphreys W.G. see Hahn K.M. 471

Hunt J.T. Lee V.G. Stein P.O. Hedberg A. Liu E.C.–K. McMullen D. and **Moreland S.** Structure–activity relationships of monocyclic endo– thelin analogs 33

Huynh–Dinh T. see Meier C. 527

Hwang S.–B. see Sahoo S.P. 327

Ialenti A. see Fattorusso 639

Ichikawa Y. see Dumas D.P. 425

Ishikawa T. Yoneda F. Tanaka K. and **Fuji K.** Synthesis and properties of oligothymidylate containing sulfur–modified thymidine: effect of thiation of pyrimidine ring on the thermo– stability and con– formation of the duplex 523

Ishizaki T. see Boger D.L. 115

Ishizaki T. see Boger D.L. 55

Jack T. see Middlemiss D. 711

Jackson P.F. Davenport T.W. Resch J.F. Lehr G.S. and **Pullan L.M.** Tricyclic quinoxalines as ligands for the strychnine–insen– sitive glycine site 751

Jaen J.C. Caprathe B.W. Wise L.D. Smith S.J. Pugsley T.A. Heffner T.G. and **Meltzer L.T.** Novel 4,5,6,7–tetrahydrobenzothiazole dopamine agonists display very low stereoselectivity in their interaction with dopamine receptors 189

Jaen J.C. Caprathe B.W. Wise L.D. Pugsley T.A. Meltzer L.T. and **Heffner T.G.** Synthesis and dopaminergic activity of the enantiomers of 6–methyl–4,5,5a,6,7–hexahydrot hiazolo[4,5–*f*]quinolin–2– amine (PD 128483) 539

Jakubowski J.A. see Berglund R.A. 649

Jakubowski J.A. see Hardinger S.A. 73

Jakubowski J.A. see Hardinger S.A. 79

Jakubowski J.A. see Ladouceur G. 173

Jakubowski J.A. see Nevill C.R.,Jr. 83

Jakubowski J.A. see Neville C.R.,Jr. 77

Jamelson F.A. see Ojima I. 581

Janda K.D. see McLeod D.A. 653

Jansze J.–P. see Dreef C.E. 239

Jaurand G. see Duchaussoy P. 95

Jayaweera G.D.S.A. MacNeil S.A. Trager S.F. and **Blackburn G.M.** Synthesis of 2–substituted–1,3,4–thiadiazole– 5–sulphonamides as novel water–soluble inhibitors of carbonic anhydrase 407

Jennings H.J. see Pozsgay V. 391

Jin H. see Mansour T.S. 757

Jin Q. see Boger D.L. 115

Johnson J.L. see Hendrickson E.K. 615

Johnson J.L. see Hendrickson E.K. 619

Johnson S.J. see Hobbs S.H. 147

Joksimovic J. see Kostic S. 403

Jones B.C.N.M. see McGuigan C. 607

Jones B.C.N.M. see McGuigan C. 729

Jones R.C.F. Tankard M. and **Higton A.M.** Studies towards a hydrophobic serine protease model 353

Joslyn B.L. see Quagliato D.A. 39

Joslyn B.L. see Soll R.M. 591

Joullie M.M. see Han S.Y. 579

Jung M. Yu D. Bustos D. ElSohly H.N. and **McChesney J.D.** A concise synthesis of 12–(3'–hydroxy–n–propyl)–deox oartemisinin 741

Jung S. see Bakker A.V. 585

Jungheim L.N. see Shepherd T.A. 21

Kamal A. and **Reddy B.S.P.** Enzymatic regiospecific oxida– tive conversion of 5–thio to 5–oxo by baker's yeast in 5,11–dithiopyrrolo[1,4]benzodia zepine 159

Kant J. see Georg G.I. 125

Kasai N. see Suzuki T. 343

Keith D.D. see Wei C.–C. 43

Keith R.H. see Djuric S.W. 179

Kemp A. Tedford M.C. and **Suckling C.J.** Substrate activated time dependent inhibition of carboxypeptidase A by aminocyclo– propane carboxylic acid derivatives and analogues 557

Kesten S.R. see Hobbs S.H. 147

Kim D.H. Shin Y.S. and **Kim K.B.** The structural feature of S1'subsite of car– boxypeptidase A 317

Kim D.H. and **Kim K.B.** The function of S1'subsite pocket of carboxypeptidase A 323

Kim H.K. see Lee Y.H. 287

Kim K.B. see Kim D.H. 317

Kim K.B. see Kim D.H. 323

Kinchington D. see McGuigan C. 729

Kinjo J. see Hebel D. 357

Kirk K.L. see Hebel D. 357

Kitazume T. see Yamazaki T. 271

Kitos J.C. see Boger D.L. 313

Kitos P.A. see Boger D.L. 115

Kitos P.A. see Boger D.L. 313

Kitos P.A. see Boger D.L. 55

Klose J.R. see Fitzhugh A.L. 155

Koga T. see Watanabe Y. 399

Kostic S. Soskic V. and **Joksimovic J.** Synthesis and evaluation of several catechol bioisosteres as potential dopamine receptor ligands 403

Kovacs T. see Hebel D. 357

Krief A. Pasau P. and **Quere L.** Comparison of the behaviour of

oxidosqualene cyclasses from pig liver and yeast toward epoxy– squalene analogues possessing a 18–19*Z* or *E* C, C double bond 365

Kubiak C.P. see Rudnicki S.M. 451

Kukla M.J. see Ho C.Y. 531

Kumar A. see Dike S.Y. 383

Kumar H.M.S. see Rama Rao K. 507

Kuo C.–H. see Sahoo S.P. 327

La Colla P. see Massa S. 575

Ladouceur G. Mais D.E. Jakubowski J.A. Utterback B.G. and **Robertson D.W.** Structural homologies among thromboxane (TXA)2) receptor antagonists: minimal pharmacophoric requirements for high affinity interaction with TXA2 receptors 173

Lafarge–Frayssinet C. see Bessodes M. 361

Lam M.–H. see Sahoo S.P. 327

Lanzetta R. see Della Greca M. 599

Lanzotti V. see Fattorusso E. 639

Lee M. and **Phillips R.S.** Synthesis and resolution of 7–fluorotryptophans 477

Lee M. White L.A. Nobles J.A. Forrow S.M. and **Hartley J.A.** Synthesis and DNA binding properties of an amidine–linked and phenyl–containing analogue of distamycin A 595

Lee S.J. see Soll R.M. 591

Lee V.G. see Hunt J.T. 33

Lee Y.H. Kim H.K. Youn I.K. and **Chae Y.B.** Synthesis of novel 1'–nitrogen replaced carbocyclic thymidine analogs as potential anti AIDS agents 287

Lehnert E.K. see Huber S.K. 243

Lehr G.S. see Jackson P.F. 751

Lehr G.S. see Resch J.F. 519

Lei P.S. see Duchaussoy P. 99

Leonard S.F. see Skiles J.W. 69

Lesiak K. see Hebel D. 357

Leveille C. see Prasit P. 645

Levin J.I. Epstein J.W. Beer B. Dean W.D. Dusza J.P. Tseng S.–S. Schweitzer H.J. Francisco G.D. Cain W.T. Bartus R.T. and **Dean R.L.,III.** Synthesis of sub– stituted 5–amino– 8–phenyl–3H,6H–1,4,5α,8α–tet raazaace– naphthalen–3–ones, a new class of agents for the improvement of cognition 435

Levy M.A. see Holt D.A. 27

Lewander T. see Liu Y. 257

Li W. see Wipf P. 745

Li Z.–H. see Burke T.R.,Jr. 165

Linn B. see Blizzard T. 369

Lipinski C.A. see Desai M.C. 411

Lippi A. see Bellucci G. 121

Liston D.R. see Desai M.C. 411

Liu E.C.–K. see Hunt J.T. 33

Liu J. see Albers M.W. 205

Liu Y. Svensson B.E. Yu H. Cortizo L. Ross S.B. Lewander T. and **Hacksell U.** C8–Substituted derivatives of 2–(dipropylamino)tetra–lin: palladium– catalyzed synthesis and interaction with 5–HT1A–receptors 257

Logusch E.W. see Walker M.C. 683

Long K.P. see Lowe J.A.,III 129

Lormeau J.C. see Duchaussoy P. 99

Lowe J.A.,III Drozda S.E. Snider R.M. Longo K.P. and **Bordner J.** Preparation and radiolabelling of CP–96,345, the first non–peptide sub– stance P antagonist 129

Lowe J.B. see Dumas D.P. 425

Lown J.W. see Gmeiner W.H. 487

Loza M. Verde I. Castro M.E. Orallo F. Fontenla J.A. Calleja J.M. Ravina E. Cortizo L. and **de Ceballos M.L.** 5HT2 antagonist activity of 3–aminomethyltetralones 717

Lu G.–Y. see Chern J.–W. 571

Luell S. see Sahoo S.P. 327

Luis S.V. Burguete M.I. Gavina F. Costero A.M. and **Rebek J.,Jr.** Enhanced transport through binding cooperativity in a circulating system 87

Lumley P. see Campbell I.B. 689

Lumley P. see Campbell I.B. 695

Lumley P. see Campbell I.B. 699

Luo W. see Gmeiner W.H. 487

Macdonald T.L. see Hahn K.M. 471

Macdonald T.L. see Huber S.K. 243

MacIntyre D.E. see Sahoo S.P. 327

MacIntyre E. see Prasit P. 645

MacNeil S.A. see Jayaweera G.D.S.A. 407

Magno S. see Fattorusso E. 639

Mahoney E.M. see Misra R.N. 295

Mai A. see Massa S. 575

Mais D.E. see Ladouceur G. 173

Mangoni L. see Della Greca M. 599

Mansour T.S. and **Jin H.** Synthesis of (+/–)–1'–aza–carbocyclic–pyrim idine–2',3'–dideo xynucleoside analogues as poten– tial anti–HIV agents 757

Mansuri M.M. Farina V. Starrett J.E.,Jr. Benigni D.A. Brankovan V. and **Martin J.C.** Preparation of the geometric isomers of ddC, ddA, d4C and d4T as potential anti–HIV agents 65

Marcolina L.M. see Douglas K.A. 267

Margiatto G. see Blizzard T. 369

Marioni F. see Bellucci G. 121

Marongiu M.E. see Massa S. 575

Marquez V.E. see Burke T.R.,Jr.

165

Martin J.C. see Mansuri M.M. 65

Massa S. Artico M. Mai A. Ragno R. Corelli F. Pani A. Marongiu M.E. Tramontano E. and **La Colla P.** Synthesis of new disoxaril analogues with potent and selective anti–human rhinovirus 14 activity 575

Maycock A.L. see Hagmann W.K. 545

Mayer R.J. see Dreyer G.B. 151

Mayer S.C. see Han S.Y. 579

Mayol L. see Fattorusso E. 639

Mayr G.W. see Dreef C.E. 239

McChesney J.D. see Jung M. 741

McCowan J.R. see Yu M.J. 107

McDonald I.A. see Salituro F.G. 455

McDonald I.A. see Whitten J.P. 441

McFarlane C.S. see Prasit P. 645

McGuigan C. Jones B.C.N.M. and **Riley P.A.** Trans–esterification reactions yield novel masked phosphate derivatives of the anti–cancer agent araC 607

McGuigan C. Jones B.C.N.M. Devine K.G. Nicholls S.R. O'Connor T.J. and **Kinchington D.** Attempts to introduce chemotherapeutic nucleotides into cells: studies on the anti– HIV agent FDT 729

McKee J.A. and **Miller M.J.** Synthesis, siderophore, and antimicrobial evaluation of a spermidine–based tricatecholate siderophore and carbacephalosporin conjugate 513

McLeod D.A. Brinkworth R.I. Ashley J.A. Janda K.D. and **Wirsching P.** Phosphonamidates and phosphonamidate esters as HIV–1 protease inhibitors 653

McMullen D. see Hunt J.T. 33

Meade E.A. and **Townsend L.B.** Synthesis of 4–amino–1–(β–D–ribofuranosyl)pyrrolo[2,3–*d*]pyri dazine; an entry into a novel series of adenosine analogs 111

Meek T.D. see Dreyer G.B. 151

Meier C. and **Huynh–Dinh T.** O–Alkyl–5',5'–dinucleoside–ph osphates as combined prodrugs of antiviral and anti– biotic compounds 527

Meltzer L.T. see Jaen J.C. 189

Meltzer L.T. see Jaen J.C. 539

Metcalf B.W. see Dreyer G.B. 151

Metcalf B.W. see Holt D.A. 27

Meurer R. see Sahoo S.P. 327

Meyer D.L. see Shepherd T.A. 21

Michel I.M. see Misra R.N. 461

Mickel S.J. see Campbell M.M. 247

Middlemiss D. Drew G.M. Ross B.C. Robertson M.J. Scopes D.I.C. Dowle M.D. Akers J. Cardwell K. Clark K.L. Coote S. Eldred C.D. Hamblett J. Hilditch A. Hirst G.C. Jack T. Montana J. Panchal T.A. Paton J.M.S. Shah P. Stuart G. and **Travers A.** Bromobenzofurans: a new class of potent, non–peptide an– tagonists of angio– tensin II 711

Mikkilineni A.B. see Ueda Y. 737

Miller L.P. see Nair V. 481

Miller M.J. see McKee J.A. 513

Millet–Paillusson C. see Alazard J.–P. 725

Mills K. see Campbell I.B. 689

Mills K. see Campbell I.B. 695

Mills K. see Campbell I.B. 699

Misra R.N. Botti C.M. Haslanger M.F. Engebrecht J.R. Mahoney E.M. and **Ciosek C.P., Jr.** Cyclic aryl hydrox– amic acids: synthesis and inhibition of 5–lipoxygenase 295

Misra R.N. Brown B.R. Sher P.M. Patel M.M. Goldenberg H.J. Michel I.M. and **Harris D.N.** Interphenylene 7–oxabicyclo[2.2.1]heptanes, SQ 33,961: a new potent, long– acting thromboxane antagonist 461

Misra R.N. Brown B.R. Harris D.N. and **Pudzianowski A.T.** Conformationally–restricted analogs of TXA2 antagonist SQ 33,961: receptor binding conformation of the carboxyl sidechain 465

Miyashiro J.M. see Djuric S.W. 179

Monaco P. see Della Greca M. 599

Montana J. see Middlemiss D. 711

Montserret R. see Herscovici J. 721

Moos W.H. see Hobbs S.H. 147

Moreland S. see Atwal K.S. 291

Moreland S. see Hunt J.T. 33

Morin M.E. see Soll R.M. 591

Mrozik H. see Blizzard T. 369

Muench D. see Whitten J.P. 441

Munk S.A. see Boger D.L. 115

Myers J.B. see Boger D.L. 313

Myers S.L. see Hobbs S.H. 147

Nagarathnam D. see Cushman M. 211

Nagarathnam D. see Cushman M. 215

Nagel A.A. see Bakker A.V. 585

Naharisoa H. see Chavanieu A. 299

Nair R.P. see Dumas D.P. 425

Nair V. Fasbender A.J. Miller L.P. and **Bruce J.L.** High selectivity of novel isoguanosine analogues for the adenosine A1 receptor 481

Ner D.H. see Dike S.Y. 383

Nevill C.R.,Jr. Jakubowski J.A. and **Fuchs P.L.** Triply–convergent synthesis of two sets of homochiral cyclopent[*a*]indene carbacyclin analogs 83

Neville C.R.,Jr. Braish T.F. Jakubowski J.A. and **Fuchs P.L.** Total synthesis of homochiral arene– fused prostacyclin analog 77

Nicholls S.R. see McGuigan C. 729

Nixon J.S. see Albers M.W. 205

Nobles J.A. see Lee M. 595

Nyce P.L. see Whitten J.P. 441

O'Connor T.J. see McGuigan C. 729

O'Grady L.A. see Hagmann W.K. 545

O'Leary M.H. see Walker M.C. 683

Obaza–Nutaitis J. see Huber S.K.

243

Ogasawara T. see Watanabe Y. 399

Oh H.–J. see Holt D.A. 27

Ojima I. and **Jamelson F.A.** A new potent inhibitor for angio– tensin converting enzyme: (*R,S*)–captopril–f3 581

Orallo F. see Loza M. 717

Oshiro G. see Soll R.M. 591

Osinga D.G. see Hagmann W.K. 545

Owen T.C. see Barltrop J.A. 611

Ozaki S. see Watanabe Y. 399

Panchal T.A. see Middlemiss D. 711

Pani A. see Massa S. 575

Paradkar V.M. see Grunewald G.L. 59

Parratt M.J. see Geen G.R. 347

Partyka R.A. see Ueda Y. 737

Pasau P. see Krief A. 365

Patel D.V. and **Gordon E.M.** C–2 Desmethyl seco–mevinic acids. Monocyclic HMG– CoA reductase inhibitors 509

Patel M.M. see Misra R.N. 461

Paton J.M.S. see Middlemiss D. 711

Paulson J.C. see Pozsgay V. 391

Pavia A.A. Pucci B. Riess J.G. and **Zarif L.** New fluorinated biocompatible non– ionic telomeric amphiphiles bearing trishydroxymethyl groups 103

Pavia M.R. see Hobbs S.H. 147

Penning T.D. see Djuric S.W. 179

Perez–Sala D. see Albers M.W. 205

Peterson L. see Prasit P. 645

Petitou M. see Duchaussoy P. 95

Petitou M. see Duchaussoy P. 99

Phillips R.S. see Andrade M.A.C. 373

Phillips R.S. see Lee M. 477

Pichon C. see Aplin R.T. 503

Piechuta H. see Prasit P. 645

Pike N.B. see Campbell I.B. 699

Pinto G. see Fiorentino A. 673

Pinto P.A. see Girijavallabhan V.M. 349

Pluscec J. see Gordon E.M. 161

Pluscec J. see Gordon E.M. 61

Pollio A. see Fiorentino A. 673

Pon R.T. see Gmeiner W.H. 487

Ponpipom M.M. see Sahoo S.P. 327

Poolman J.T. see Boons G.J.P.H. 303

Potter B.V.L. see Sawyer D.A. 705

Pozsgay V. Guadino J. Paulson J.C. and **Jennings H.J.** Chemo–enzymatic synthesis of a branching deca– saccharide fragment of the capsular polysaccharide of type III group B *Streptococcus* 391

Prasit P. Belley M. Evans J.F. Gauthier J.Y. Leveille C. McFarlane C.S. MacIntyre E. Peterson L. Piechuta H. Therien M. Young R.N. and **Zamboni R.** A new class of leukotriene biosynthesis inhib– itors: the develop– ment of ((4–(4–chlorophenyl)–1–(4–(2–quinolinylmethoxy)phenyl)–butyl)–thio)acetic acid, L–674,636 645

Prestwich G.D. see Bai M. 227

Previtera L. see Della Greca M. 599

Previtera L. see Fiorentino A. 673

Pucci B. see Pavia A.A. 103

Pudzianowski A.T. see Misra R.N. 465

Pugsley T.A. see Jaen J.C. 189

Pugsley T.A. see Jaen J.C. 539

Pullan L.M. see Jackson P.F. 751

Purandare A.V. see Rama Rao A.V. 201

Quagliato D.A. Humber L.G. Joslyn B.L. Soll R.M. Browne E.N.C. Shaw C. and **Van Engen D.** The synthesis and structural charac– terization of WAY–120,491; a novel potassium channel activator 39

Quagliato D.A. see Soll R.M. 591

Quere L. see Krief A. 365

Ragno R. see Massa S. 575

Raja F. see Guerrero A. 675

Rama Rao A.V. Purandare A.V. and **Singh A.K.** Enantiospecific synthesis of 14*S*,15*S* leukotriene A4 methyl ester 201

Rama Rao K. and **Kumar H.M.S.** Baker's yeast catalysed oxidative coupling of thiols to disulfides 507

Rampulla M.S. see Combs D.W. 133

Rando R.R. see Albers M.W. 205

Ratcliffe G. see Horwell D.C. 169

Ravina E. see Loza M. 717

Ray P.C. see Chauhan S.M.S. 601

Ream J.E. see Walker M.C. 683

Rebek J.,Jr. see Luis S.C. 87

Rebek J.,Jr. see Tadayoni B.M. 13

Reddy B.S.P. see Kamal A. 159

Reily M.D. see Cody W.L. 415

Resch J.F. Lehr G.S. and **Wischik C.M.** Design and synthesis of potential affinity/ cleaving reagent for beta–pleated sheet protein structures 519

Resch J.F. see Jackson P.F. 751

Riche C. see Alazard J.–P. 725

Riess J.G. see Pavia A.A. 103

Riley P.A. see McGuigan C. 607

Roberts E. see Horwell D.C. 169

Robertson D.W. see Ladouceur G. 173

Robertson G.M. see Campbell I.B. 695

Robertson G.M. see Campbell I.B. 699

Robertson M.J. see Middlemiss D. 711

Rodriguez J.B. Gros E.G. and **Stoka A.M.** Synthesis and biological activity of juvenile hormone analogues (JHA) for *Trypanosoma cruzi* 679

Roelen H.C.P.F. see Dreef C.E.

239

Roessner C.A. see Aplin R.T. 503

Ross B.C. see Middlemiss D. 711

Ross S.B. see Liu Y. 257

Rudnicki S.M. Stankus A.A. Kubiak C.P. and **Suggs J.W.** Nicking of supercoiled DNA via metal radicals generated from photolysis of species containing metal– metal bonds 451

Sahoo S.P. Graham D.W. Acton J. Biftu T. Bugianesi R.L. Girotra N.N. Kuo C.–H. Ponpipom M.M. Doebber T.W. Wu M.S. Hwang S.–B. Lam M.–H. MacIntyre D.E. Bach T.J. Luell S. Meurer R. Davies P. Alberts A.W. and **Chabala J.C.** Synthesis and biological activity of MK 287 (L–680,573) a potent, specific and orally active PAF receptor antagonist 327

Sakya S.M. see Boger D.L. 115

Salituro F.G. Tomlinson R.C. Baron B.M. Demeter D.A. Weintraub H.J.R. and **McDonald I.A.** Design, synthesis and molecular modeling of 3–acylamino–2–carboxyindole NMDA receptor glycine–site antagonists 455

Sammons R.D. see Walker M.C. 683

Samuelsson B. see Yuan W. 551

Sarre O.Z. see Girijavallabhan V.M. 349

Sawyer D.A. and **Potter B.V.L.** Total synthesis of L–2,2–difluoro–2–deoxy–*myo*–inositol 14,5–tris– phosphate, a potent inhibitor of the enzymes of D–*myo*–inositol 1,4,5–triphosphate metabolism 705

Schofield C.J. see Aplin R.T. 503

Schofield C.J. see Baldwin J.E. 421

Schofield C.J. see Baldwin J.E. 9

Schreiber S.L. see Albers M.W. 205

Schwarz R.D. see Hobbs S.H. 147

Schweiger E.J. see Han S.Y. 579

Schweitzer H.J. see Levin J.I. 435

Scopes D.I.C. see Middlemiss D. 711

Scott A.I. see Aplin R.T. 503

Sekhar V. see Wipf P. 745

Shah P. see Middlemiss D. 711

Shah S.K. see Hagmann W.K. 545

Shamsazar J. see Bessodes M. 361

Shaw C. see Quagliato D.A. 39

Shepherd T.A. Jungheim L.N. Meyer D.L. and **Starling J.J.** A novel targeted delivery system utilizing a cephalosporin – oncolytic prodrug activated by an antibody β–lactamase conjugate for the treatment of cancer 21

Sher P.M. see Misra R.N. 461

Shiau C.–Y. see Chern J.–W. 571

Shin Y.S. see Kim D.H. 317

Sikorski J.A. see Walker M.C. 683

Simpson T.J. see Dillon M.P. 223

Sinay P. see Duchaussoy P. 99

Singh A.K. see Rama Rao A.V. 201

Singh G. see Campbell M.M. 247

Skiles J.W. Fuchs V. and **Leonard S.F.** Imidazo[1,2–*a*]piperazines as mechanistic inhibitors of serine proteinases 69

Smith B.D. see Baldwin J.E. 9

Smith S.J. see Jaen J.C. 189

Snider R.M. see Lowe J.A.,III 129

Soll R.M. Quagliato D.A. Deininger D.D. Dollings P.J. Joslyn B.L. Dolak T.M. Lee S.J. Bohan C. Wojdan A. Morin M.E. and **Oshiro G.** Antihypertensive benzopyran–related potassium channel activators: a role for lipophilicity 591

Soll R.M. see Quagliato D.A. 39

Somerville R.L. see Walker M.C. 683

Soskic V. see Kostic S.

Spencer R.W. see Bakker A.V. 585

Spencer R.W. see Desai M.C. 411

Stankus A.A. see Rudnicki S.M. 451

Starling J.J. see Shepherd T.A. 21

Starrett J.E.,Jr. see Mansuri M.M. 65

Stein P.O. see Hunt J.T. 33

Stoka A.M. see Rodriguez J.B. 679

Stolowich N.J. see Aplin R.T. 503

Stoss P. and **Erhardt S.** Monodeoxy–1,4,3,6–dianhydroh exitol nitrates 629

Stuart G. see Middlemiss D. 711

Subramanyam C. and **Bell M.R.** A general synthesis of 4–alkyl/aryl substituted saccharins 733

Suckling C.J. see Kemp A. 557

Suggs J.W. see Rudnicki S.M. 451

Suntornwat O. see Boger D.L. 313

Suntornwat O. see Boger D.L. 55

Suzuki T. and **Kasai N.** A novel method for the generation of (*R*)– and (*S*)–3–chloro–2–propanediol by stereospecific dehalogenating bacteria and their use in the preparation of (*R*)– and (*S*)–glyci– dol 343

Svensson B.E. see Liu Y. 257

Sweeney J.B. see Dillon M.P. 223

Tadayoni B.M. and **Rebek J.,Jr.** Intramolecular nucleophilic displacement reactions at carboxyl oxygen 13

Tanaka K. see Ishikawa T. 523

Tankard M. see Jones R.C.F. 353

Taschner M.J. and **Chen Q.–Z.** The enzymatic Baeyer–Villiger oxidation: synthesis of the C11–C16 subunit of ionomycin 535

Tedford M.C. see Kemp A. 557

Tellier F. New stereospecific synthesis of (*E,E,Z*)– and (*E,E,E*)–10,12, 14–hexadecatrienal, sex pheromonal components of *Manducta sexta* 635

ter Laak A.M. see Zhang M.–Q. 387

Thadeio P.F. see Desai M.C. 411

Thal C. see Alazard J.–P. 725

Therien M. see Prasit P. 645

Thompson K.R. see Hagmann

W.K. 545

Timmerman H. see Zhang M.–Q. 387

Tomlinson R.C. see Salituro F.G. 455

Torrence P.F. see Hebel D. 357

Townsend L.B. see Meade E.A. 111

Trager S.F. see Jayaweera G.D.S.A. 407

Tramontano E. see Massa S. 575

Travers A. see Middlemiss D. 711

Tsai B.–S. see Djuric S.W. 179

Tseng S.–S. see Levin J.I. 435

Ueda Y. Mikkilineni A.B. and **Partyka R.A.** Synthesis of α–(S)–acylamino–N–(hydroxydi oxocyclobutenyl)–γ–lactams 737

Utterback B.G. see Ladouceur G. 173

van Boeckel C.A.A. see Vos J.N. 143

van Boom J.H. see Boons G.J.P.H. 303

van Boom J.H. see Dreef C.E. 239

van der Marel G.A. see Boons G.J.P.H. 303

van der Marel G.A. see Dreef C.E. 239

Van Engen D. see Quagliato D.A. 39

Vander Jagt D.L. see Houston M.E.,Kr. 623

Verde I. see Loza M. 717

Villani–Price D. see Djuric S.W. 179

Vincent L.A. see Bakker A.V. 585

Vinick F.J. see Bakker A.V. 585

Vos J.N. Westerduin P. and **van Boeckel C.A.A.** Synthesies of a 6–0–phosphorylated analogue of the antithrombin III binding sequence of heparin: replacement of one essential sulphate group by a phosphate group nulifies the biological activity 143

Wadsworth J. see Albers M.W. 205

Walker M.C. Ream J.E. Sammons R.D. Logusch E.W. O'Leary M.H. Somerville R.L. and **Sikorski J.A.** Structural require– ments for PEP binding to EPSP synthase 683

Wallis C.J. see Campbell I.B. 689

Wang K.–T. see Chen S.–T. 445

Wang K.–T. see Wu S.–H. 339

Warren M.J. see Aplin R.T. 503

Watanabe Y. Hirata M. Ogasawara T. Koga T. and **Ozaki S.** Synthesis and characterization of a photoaffinity probe possessing biotinyl and azidobenzoyl moieties for IP3–affiniated protein 399

Watts I.S. see Campbell I.B. 695

Watts I.S. see Campbell I.B. 699

Wei C.–C. Christenson J.G. Corraz A.J. and **Keith D.D.** (2,3)–α–Methylenepenicillanic acid sul– fone: synthesis and β–lactamase in– hibiting properties 43

Weintraub H.J.R. see Salituro F.G. 455

Werbovetz K.A. see Huber S.K. 243

Werness S. see Cody W.L. 415

Westerduin P. see Vos J.N. 143

Weston H. see Hagmann W.K. 545

Wetterholn A. see Yuan W. 551

Wharton K. see Campbell I.B. 695

White B.P. see Campbell I.B. 689

White L.A. see Lee M. 595

Whitten J.P. Muench D. Cube R.V. Nyce P.L. Baron B.M. and **McDonald I.A.** Synthesis of 3(*S*)–phosphonoacetyl–2(*R*)–piperidin ecarboxylic acid, a confor– mationally–restricted glutamate antagonist 441

Wier P.J. see Holt D.A. 27

Wilkinson S.E. see Albers M.W. 205

Williams I.H. see Desai M.C. 411

Wipf P. Li W. and **Sekhar V.** Synthesis of chemoreversible prodrugs of ARA–C 745

Wirsching P. see McLeod D.A. 653

Wischik C.M. see Resch J.F. 519

Wise L.D. see Jaen J.C. 189

Wise L.D. see Jaen J.C. 539

Wojdan A. see Soll R.M. 591

Wong C.–H. see Dumas D.P. 425

Wong C.–H. see Yuan W. 551

Wood M.E. see Baldwin J.E. 421

Woster P.M. see Douglas K.A. 267

Wu M.S. see Sahoo S.P. 327

Wu S.–H. Chu F.–Y. and **Wang K.–T.** Reversible enantioselectivity of enzymatic reactions by media 339

Xiao X. see Bai M. 227

Yamazaki T. Haga J. and **Kitazume T.** Preparation and evaluation of optically active 4,4–difluorothreonine as a potent novel antitumor material 271

Yen H.–K. see Holt D.A. 27

Yohannes D. see Boger D.L. 313

Yoneda F. see Ishikawa T. 523

Youn I.K. see Lee Y.H. 287

Young R.N. see Prasit P. 645

Yu D. see Jung M. 741

Yu H. see Liu Y. 257

Yu M.J. McCowan J.R. Bertsch B. and **Ho P.P.K.** Enzymic and nonenzymic lipid peroxidation: in– hibition by substi– tuted phenoxazines 107

Yuan W. Zhong Z. Wong C.–H. Haeggstrom J.Z. Wetterholn A. and **Samuelsson B.** Probing the inhibition of leukotriene A4 hydrolase based on its aminopeptidase activity 551

Zamboni R. see Prasit P. 645

Zarif L. see Pavia A.A. 103

Zarrinmayeh H. see Boger D.L. 55

Zhang M.–Q. ter Laak A.M. and **Timmerman H.** Optical isomers of the H1 antihistamine terfenadine: synthesis and activity 387

Zhong Z. see Yuan W. 551

Zhu G. see Cody W.L. 415

Zormeier M.M. see Douglas K.A. 267

Bioorganic & Medicinal Chemistry Letters
Instructions to Contributors

Bioorganic and Medicinal Chemistry Letters (*BioMed. Chem. Lett.*) seeks to publish experimental or theoretical research results of outstanding significance and timeliness in the fields of bio-organic chemistry, medicinal chemistry, and related disciplines. Publications are to be in the form of rapid communications and in order to achieve rapid publication, all contributions to the journal are reproduced directly from the author's typescript (camera-ready manuscripts only).

Journal Policy: The language of submission is English only. All papers are submitted to referees who advise the Editor on the matter of acceptance in accordance with the high standards required with the understanding that the subject matter has not been previously published and is not under consideration elsewhere. Referees will be asked to distinguish contributions meeting the above requirements and having an element of novelty, timeliness, and urgency that merits publication in rapid communication format from otherwise meritorious work that more appropriately awaits publication in complete form accompanied with full experimental details. Referee names are not disclosed but their views are forwarded by the Editor to the authors for consideration. Authors accept full responsibility for the factual accuracy of the data presented and should obtain any authorization necessary for publication. As such the contents of the papers are the sole responsibility of the authors and publication shall not imply the concurrence of the Editors or Publisher. Authors are encouraged to suggest names of several experts in the field when papers are first submitted or at any time in the evaluation process. The typewritten manuscript is reproduced photographically and each communication is a separate entry in the journal. Authors are requested to send papers of 2, 4, or 6 pages in a format that follows that established for *Tetrahedron Letters*.

Graphical Abstracts: Authors must supply a graphical abstract in finished, camera-ready form at the time the communication is first submitted. The abstract should summarize the contents of the communication in a concise, pictorial form designed to capture the attention of a wide readership and for compilation of databases. Carefully drawn chemical structures are desired which serve to illustrate the theme of the communication. The manuscript title, authors, author affiliation and address, and appropriate text (i.e., abstract) should be incorporated not to exceed the space limitations (5 x 20 cm). In publication, the graphical abstracts will be reduced by 25%.

PREPARATION OF MANUSCRIPTS

Manuscripts should be typed at one and a half spaces using black type on good quality white bond paper in a manner that ensures a clean, clear impression on the letters. Any good quality paper may be used provided the actual typing area fills the space detailed below. Manuscripts will be reduced by a factor of 25% and the journal margins are provided during reproduction reduction. For papers composed on a word processor, letter quality printers must be used and dot matrix printer manuscripts will not be accepted.

Title: The title should be in all capital letters, preferably in bold face type, centered on the width of page 1 with the title 2 cm from the top of the page. The title should be brief, specific, and rich in informative words.

Authors: After one line of space from the title, the authors' names and addresses should be provided on separate lines, centered on the width of the page, capitalizing the first letter of all main words. The author(s) to whom correspondence should be addressed by readers should be indicated with an asterisk.

Abstract: Authors must include a short abstract of no more than four lines typed in single space in regular typeface. With appropriate spacing this is placed immediately after the authors' address and before the text of the communication. This should be clearly labeled as the abstract preferably with the word **Abstract.** in boldface type.

Manuscript: In the introductory section of the communication, the author should strive to define the significance of the work and the justification for its rapid communication. The typing area of page 1 including the title must be 19 cm wide by 24 cm deep. The typing area of the remaining pages must be extended to cover an area of 19 cm wide by 26 cm deep (8 1/2" x 11" paper). Where new techniques or methods are described, a typical experimental procedure may be provided.

Acknowledgment: Following the manuscript text and preceding the references an acknowledgment section may be included. This should be typed in single space in regular typeface, and clearly labeled as the acknowledgment section with the word **Acknowledgment.** preferably in boldface type.

References and Notes: References to the literature should follow the format outlined for ACS publication (e.g., Journal of the American Chemical Society), titles of journals are abbreviated according to *Chemical Abstracts Service Source Index*, should be numbered consecutively as they appear throughout the text, and be indicated consecutively in the text with superscript numbers. The reference section should be typed in single space or one and a half space in regular typeface and clearly labeled as the reference section with the words **References and Notes** preferably in boldface type.

Scientific Articles:

1. Doe, J. S.; Smith, J.; Roe, P. *J. Am. Chem. Soc.* **1968**, *90*, 8234.

Books:

2. Doe, J. S.; Smith, J. *Medicinal Chemistry*; Roe, P., Ed.; Pergamon Press: Oxford, 1990; Vol 1, pp. 301-383.

Camera-Ready Requirements. Formulas, Tables, and Black and White or Color Photographs: To maintain a finished, high quality, artistic appearance of the journal, authors are asked to use whatever resources are available to them to produce manuscripts that are of pleasing appearance. Direct reproduction of camera-ready manuscripts requires the authors to provide the manuscript in a finished artistic format, making the best possible use of the space within an even number of completely utilized pages. Formulas and other graphical material should be drawn with special care directly on the original manuscript or carefully pasted in the manuscript exactly as the page is to appear in the journal. No freehand illustration will be accepted. The size of the formulas may vary according to the nature of the illustration but these should be neither overpowering nor so small that they are hard to read after reduction by a factor of 25%. High quality glossy prints of black and white photographs (e.g., high contrast gels) can be directly reproduced with inclusion in the manuscript. An example may be found in *BioMed. Chem. Lett.* **1991**, *1*, 118. These should be submitted as originals on each of the original and review manuscripts at the time of submission. Photocopies of such gels should be considered unacceptable. A limited number of color figures may be published in the journal. The criterion for accepting the inclusion of a color figure will be that it must contribute to the scientific and informational content of the published work. Authors may expect a short delay in the publication of articles containing a color figure (up to 4 additional weeks) to allow for careful reproduction of the color illustration. At present, manuscripts submitted with color figures should be submitted with original glossy photographs on each of the original and review manuscripts at the time of submission. Black and white photocopies of color figures should be considered unacceptable although high quality color copies of color photographs and original figures printed from high resolution color printers may prove acceptable. As technology in this area of publications continues to improve the journal will strive to develop along with the technology. The Editor may return otherwise acceptable papers for modification if the quality of the figures or structural formulas is poor or the overall layout is carelessly composed.

Biological Data: Biological test methods must be referenced or described in sufficient detail to permit the experiments to be repeated by others. Standard compounds and established drugs/agents should be tested in the same system for comparison. Statistical limits (statistical significance) for the biological data are usually required. If statistical limits cannot be provided, the number of determinations and an indication of the variability and reliability of the results should be given. Doses and concentrations should be expressed in molar quantities when comparisons of potencies are made with compounds having substantial differences in molecular weights. For inactive agents, the highest concentration or dose level tested should be indicated.

Nomenclature: It is the responsibility of the authors to provide correct nomenclature. Chemical names for drugs are preferred. If these are not practical, generic names, names approved by the U.S. Adopted Names Council, or those approved by the World Health Organization may be used. If a generic name is used, its chemical name or structure should be provided at the point of first citation. Authors will find the following as useful reference books for recommended nomenclature.

IUPAC Nomenclature of Organic Chemistry; Rigaudy, J.; Klesney, S. P., Ed.; Pergamon Press: Oxford, 1979.

Enzyme Nomenclature; Webb, E. C., Ed.; Academic Press: Orlando, 1984.

Biochemical Nomenclature and Related Documents, The Biochemistry Society: London, 1978.

Trademarks: Authors are required to acknowledge the trademark protection in the standard fashion (e.g., Selectride®) although not for words which have entered general usage (e.g., pyrex).

Hazardous Materials or Procedures: Authors are requested to draw attention to hazards by adding the word CAUTION followed by a brief descriptive phrase and literature references if appropriate.

X-ray Crystallographic Data: Manuscripts reporting X-ray crystallographic data must be accompanied by lists of refined coordinates, bond distances, bond angles, torsion angles with esd's for deposition at the Cambridge Crystallographic Data Centre [see: *Tetrahedron* **1984**, *40(2)*, ii].

Software: Software used a part of computer-aided drug/agent design (e.g., molecular modeling, QSAR, conformational analysis) should be readily available from accepted sources and the authors may specify where the software can be obtained. Assurance of the quality of the parameters employed for the relevant potential functions should be detailed in the manuscripts.

Abbreviations: Standard ACS journal abbreviations should be used throughout the manuscript and are employed without periods. The preferred forms for some of the more commonly used abbreviations are mp, bp, °C, °K, min, h, mL, µL, g, mg, µg, cm, mm, nm, mol, mmol, µmol, M, mM, µM, ppm, HPLC, TLC, GC, ^{1}H NMR, GC-MS, UV, IR, EPR, ESR, DNase, ED_{50}, ID_{50}, IC_{50}, LD_{50}, im, ip, iv, mRNA, RNase, rRNA, tRNA, cpm, Ci, dpm, V_{max}, K_m, k, $t_{1/2}$. All nonstandard abbreviations should be defined following the first use of the abbreviation.

Mailing of Manuscripts: The original and three copies of the manuscript including the graphical abstract and a signed and dated copyright transfer notice should be sent to the editorial office provided below. In order to achieve the most rapid publication time possible for the communication, authors may wish to FAX a copy (supplying their own telephone and FAX numbers) to the Editor at the time that they mail the camera-ready manuscript.

Professor Dale L. Boger
Editor-in-Chief, ***Bioorganic and Medicinal Chemistry Letters***
Department of Chemistry
The Scripps Research Institute
10666 N. Torrey Pines Road
La Jolla, California 92037
USA
FAX: 1-619-554-6401
Phone: 1-619-554-7022

Corrections: If errors of consequence are in a published paper, a correction of the error should be sent to the Editor for publication in an "Additions and Corrections" section.

Reprints: Any reprints above the 50 reprints supplied free of charge must be indicated at the time of submission.

Page Charges: None

BMCL **75%**

Bioorganic & Medicinal Chemistry Letters

GRAPHICAL ABSTRACT EXAMPLE



SEND FOR A FREE SAMPLE COPY OF...

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

AN INTERNATIONAL JOURNAL ON ALL DRUG-RELATED TOPICS IN PHARMACEUTICAL, BIOMEDICAL AND CLINICAL ANALYSIS

Editor-in-Chief: **ANTHONY F FELL**, *School of Pharmaceutical Chemistry, University of Bradford, Bradford, West Yorkshire BD7 1DP, UK*
Editor (North America): **CHRISTOPHER M RILEY**, *Center for Bioanalytical Research, University of Kansas, 2095 Constant Avenue, Lawrence, Kansas 66046, USA*

This journal is an international medium for the publication of original research reports and authoritative reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical and biomedical sciences, including relevant developments in analytical methodology, instrumentation, computation and interpretation. Applications focus on individual groups of drugs, drug stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance and drug-related topics of health and safety in the pharmaceutical industry.
The journal is directed towards the needs of academic, clinical, government and industrial analysis and presents a unique forum for the discussion of current developments at the interface between pharmaceutical, biochemical and clinical analysis.

A Selection of Papers
I J KOSKI (USA), **B A JANSSON, K E MARKIDES** (Sweden) & **M L LEE** (USA), Analysis of prostaglandins in aqueous solutions by supercritical fluid extraction and chromatography.
S H NORRIS, J N JOHNSTONE, R DELEON & R ROTHLEIN (USA), A competitive ELISA for the anti-intercellular adhesion molecule-1 (anti-ICAM-1) binding activity of monoclonal antibody R6.5 in serum.
H F ASKAL & G A SALEH (Egypt), Spectrophotometric methods for the determination of sulphathiourea.
C CONFALONIERI, G CRISTINA & M FARINA (Italy), The use of a new laser particle sizer and shape analyser to detect and evaluate gelatinous microparticles suspended in reconstituted anthracycline infusion solutions.
F T DELBEKE & M DEBACKERE (Belgium), The influence of diuretics on the excretion and metabolism of doping agents - V. Dimefline.
H G PARKES, R E ALLEN, A FURST, D R BLAKE & M C GROOTVELD (UK), Speciation of non-transferrin-bound iron ions in synovial fluid from patients with rheumatoid arthritis by proton nuclear magnetic resonance spectroscopy.

Indexed/Abstracted in: *Current Awareness in Biological Sciences (CABS), Curr Cont ASCA, Excerp Med, Biosis Data, Chemical Abstracts Service, Anal Abstr, CAB Inter, Cam Sci Abstr, Curr Cont Life Sci, Curr Cont ISI/BIOMED Database, Curr Cont Sci Cit Ind, Curr Cont SCISEARCH Data*

(00690)
Subscription Information
1992: Volume 10 (12 issues)

Annual subscription (1992)	**£425.00**	**US$680.00**
Two-year rate (1992/93)	**£807.50**	**US$1292.00**

ISSN: 0731-7085

PERGAMON PRESS

Pergamon Press plc, Headington Hill Hall, Oxford OX3 0BW, UK
Pergamon Press, Inc., 395 Saw Mill River Road, Elmsford, NY 10523, USA

Advertising rate card available on request. Back issues and current subscriptions are also available in microform. Sterling prices quoted are definitive. US dollar prices are quoted for convenience only and are subject to exchange rate fluctuation. Prices shown include postage and insurance and apply worldwide except in Japan.

Did you know that if you are a contributor to any of Pergamon's Journals you are entitled to

25%

Discount on most Pergamon Books?

Contact your nearest Pergamon office in order to obtain a subject catalogue

Pergamon Press

Pergamon Press plc, Headington Hill Hall, Oxford, OX3 0BW, UK
Pergamon Press Inc., 395 Saw Mill River Road, Elmsford, New York, 10523, USA

cor017/p10

PERGAMON'S JOURNALS IN CHEMISTRY

- ❑ (00768) Applied Geochemistry
- ❑ (00228) Applied Radiation and Isotopes
- ❑ (00972) Bioorganic & Medicinal Chemistry Letters
- ❑ (00967) Chaos, Solitons and Fractals
- ❑ (00285) Chromatographia
- ❑ (00379) Computers & Chemistry
- ❑ (00205) Electrochimica Acta
- ❑ (00294) European Polymer Journal
- ❑ (00212) Geochimica et Cosmochimica Acta
- ❑ (00690) Journal of Pharmaceutical and Biomedical Analysis
- ❑ (00229) Journal of Physics and Chemistry of Solids
- ❑ (00272) Journal of Quantitative Spectroscopy & Radiative Transfer
- ❑ (00476) Organic Geochemistry
- ❑ (00284) Petroleum Chemistry USSR
- ❑ (00218) Polyhedron
- ❑ (00257) Polymer Science USSR
- ❑ (00420) Progress in Nuclear Magnetic Resonance Spectroscopy
- ❑ (00418) Progress in Polymer Science
- ❑ (00423) Progress in Reaction Kinetics
- ❑ (00417) Progress in Solid State Chemistry
- ❑ (00331) Radiation Physics and Chemistry
- ❑ (00540) Selective Electrode Reviews
- ❑ (00213) Spectrochimica Acta Part A
- ❑ (00214) Spectrochimica Acta Part B
- ❑ (00327) Spectrochimica Acta Reviews
- ❑ (00308) Talanta
- ❑ (00232) Tetrahedron
- ❑ (00937) Tetrahedron: Asymmetry
- ❑ (00233) Tetrahedron Letters
- ❑ (00730) World Surface Coatings Abstracts

FREE SAMPLE COPIES AVAILABLE ON REQUEST

Check the appropriate boxes and return this page to your nearest Pergamon office to receive a **free sample copy** of any of the journals listed above.

Name _____ Position _____

Address _____

_____

Pergamon Press plc
Headington Hill Hall
Oxford OX3 0BW, UK

Pergamon Press, Inc.
395 Saw Mill River Road, Elmsford
New York 10523, USA

JCM102.1/92

• BACK ISSUES OF •
PERGAMON INTERNATIONAL RESEARCH JOURNALS

Back issues of Pergamon journals are available in hard copy. New subscribers to a journal may purchase back issues of that publication in hard copy edition at 25% discount on the standard price. Pergamon maintains stocks of back issues and orders may be placed with confidence at your nearest Pergamon office. Should any issue of a volume be temporarily out of stock at the time of ordering, a high quality photoduplicated copy will be supplied at no extra charge to complete your order.

SAVE UP TO 25% BY PURCHASING COMPLETE SETS
Customers wishing to purchase complete sets can do so at a saving of 25% less than the individual volume price.

MICROFORM EDITIONS
Back issues in microform of Pergamon research journals are also available. For further information please apply to your nearest Pergamon office.

BACK ISSUES PRICE LIST
Full details of the rates of back issues of all Pergamon journals can be found in our Back Issues Price List. Please contact your nearest Pergamon office for a copy.

PERGAMON PRESS

Pergamon Press plc, Headington Hill Hall, Oxford OX3 0BW, UK
Pergamon Press Inc., 395 Saw Mill River Road, Elmsford NY 10523, USA

COR017/p4

Bioorganic & Medicinal Chemistry Letters

A Tetrahedron Publication for Rapid Dissemination of
Preliminary Communications on all Aspects of Bioorganic Chemistry,
Medicinal Chemistry and Related Disciplines

AIMS AND SCOPE

Bioorganic & Medicinal Chemistry Letters (*BioMed. Chem. Lett.*) presents preliminary experimental or theoretical research results of outstanding significance and timeliness on all aspects of science at the interface of chemistry and biology and on major advances in drug design and development. The journal will publish preliminary communications in camera-ready form in much the same format as *Tetrahedron Letters* and strives to provide maximum dissemination to a large, international audience, the outstanding advances in bioorganic chemistry, medicinal chemistry, and related disciplines.

Topics relevant to but not limited to the journal include:

- bioorganic chemistry, all aspects
- medicinal chemistry, all aspects
- design, synthesis, and evaluation of enzyme inhibitors
- elucidation of enzyme mechanism and structure
- chemistry of enzymatic and metabolic pathways
- biosynthesis
- kinetic, spectroscopic, isotopic, and stereochemical studies of enzymatic and metabolic reactions
- chemical models for enzymes, peptides, and biological macromolecules
- coenzyme structure and reactivity
- protein/enzyme structure–function studies
- catalyst systems that mimic enzymes
- structure, mechanism, synthesis, and evaluation of pheromones
- chemical modification of nucleic acids
- physical, chemical, biochemical, and biological aspects of nucleic acids
- DNA:agent and DNA:protein interactions
- catalytic antibodies
- enzymes in organic synthesis
- molecular recognition
- isolation, structure determination, and synthesis of bioactive agents
- bioconjugates
- molecular basis for protein function
- design, synthesis, and evaluation of biologically active agents and novel drugs
- structure–activity relationship (SAR) studies
- chemical–biological relationships, all aspects
- development of novel receptor models
- molecular modeling, conformational analysis, QSAR
- physicochemical studies on established drugs pertinent to the mechanism of action
- drug delivery
- drug metabolism, metabolic transformation of drugs
- design, synthesis, and evaluation of diagnostic agents

Printed in Great Britain at BPCC-AUP Aberdeen Ltd.